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Abstract 
 
Childhood neuroblastoma is the most common solid tumour of infancy and highly refractory to 
therapy. One of the most powerful prognostic indicators for this disease is the N-Myc gene 
amplification, which occurs in approximately 25% of all neuroblastomas. 
N-Myc is a member of transcription factors belonging to a subclass of the larger group of proteins 
sharing Basic-Region/Helix–Loop–Helix/Leucin-Zipper (BR/HLH/LZ) motif. N-Myc oncoproteins 
may determine activation or repression of several genes thanks to different protein-protein 
interactions that may modulate its transcriptional regulatory ability and therefore its potential for 
oncogenicity. Chromatin modifications, including histone methylation, have a crucial role in 
transcription de-regulation of many cancer-related genes. Here, it was investigated whether N-Myc 
can functionally and/or physically interact with two different factors involved in methyl histone 
modification: WDR5 (core member of the MLL/Set1 methyltransferase complex) and the de-
methylase LSD1.  
Co-IP assays have demonstrated the presence of both N-Myc-WDR5 and N-Myc-LSD1 complexes 
in two neuroblastoma cell lines. Human N-Myc amplified cell lines were used as a model system to 
investigate on transcription activation and/or repression mechanisms carried out by N-Myc-LSD1 
and N-Myc-WDR5 protein complexes. qRT-PCR and immunoblot assays underlined the ability of 
both complexes to positively (N-Myc-WDR5) and negatively (N-Myc-LSD1) influence 
transcriptional regulation of crititical neuroblastoma N-Myc-related genes, MDM2, p21 and 
Clusterin.  
Ch-IP experiments have revealed the binding of the N-Myc complexes above mentioned to the gene 
promoters analysed. Finally, pharmacological treatment pointed to abolish N-Myc and LSD1 
activity were performed to test cellular alterations, such as cell viability and cell cycle progression. 
Overall, the results presented in this work suggest that N-Myc can interact with two distinct histone 
methyl modifiers to positively and negatively affect gene transcription in neuroblastoma.  
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NEUROBLASTOMA, AN OVERVIEW 
 
Neuroblastoma is one of the most common, enigmatic and heterogeneous tumors it is characterized 
by different phenotypes ranging from spontaneous regression to metastatic disease (1, 2). 
Nerve cells of the sympathetic nervous system normally develop in the neural crest and 
neuroblastomas are neuro-ectodermal tumors arising from these pluripotent precursor cells (2). 
The transient migratory potential of pluripotent Neural Crest Cells (NCCs) is probably the cause 
behind the complicated and fine-regulated journey across the dynamic landscape of the developing 
embryo. This migration, finally, determines a remarkable variety of differentiated cell types, 
including sensory, autonomic, and enteric ganglia in the peripheral nervous system, the adrenal 
medulla, melanocytes and a range of skeletal, connective, adipose and endocrine cells (3).  
Neuroblastomas may arise anywhere along the sympathetic ganglia because of their neural crest 
origin. Indeed, most primary tumors (65%) occur within the abdomen, with at least half of these 
arising in the adrenal medulla. Other frequent sites of disease include the neck, chest, and pelvis. 
The disease is notable for its extensive spectrum of clinical behaviour. Although substantial recovery 
in outcome of some well-defined subgroup of patients has been registered during the past few 
decades, the outcome for children with a high-risk clinical phenotype has improved only modestly, 
with long-term survival still less than 40% (4).  
Because of its neuro-ectodermal origin, neuroblastoma can be resolved into three main clinical 
scenarios: 
• Localized tumors 
• Metastatic disease 
• 4S disease 
D'Angio and colleagues (5) first described the striking clinical phenotype of stage 4S (S=special) 
disease (about 5% of cases). Infants with this disease have small localized primary tumors with 
metastases in liver, skin, or bone marrow that almost always spontaneously regress. Neuroblastoma is 
characterized by the highest percentage of spontaneous regression or differentiation (i.e. into a 
benign ganglioneuroma) observed in human cancers: the current frequency of neuroblastoma tumors 
that are detected clinically and subsequently regress without pharmacological treatment is 5–10% 
(6). However, the amount of authentic asymptomatic neuroblastoma patients in which the tumor 
regress spontaneously is probably much higher, and might be equal to the number detected 
clinically. These clinical information arouse considerable interest in discerning the mechanisms 
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underlying spontaneous regression or differentiation, which in turn may advantage to therapeutic 
approaches to stimulate these phenomena (6).  
  
 
 
 
 
 
 
 
 
 
 
                                              Figure 1: Onset sites of Neuroblastoma (4). 
 
From a histological point of view, neuroblastomas can be classified into:  
• immature, consisting of a large population of small neuroblasts, highly undifferentiated, with 
little cytoplasm (neuroblastoma, malignant).  
• partially mature, consisting of ganglion cells (ganglioneuroblastoma, with reduced 
malignancy but capable of metastasizing)  
• fully mature ganglion cells in clusters surrounded by a dense stroma of Schwann cells 
(ganglioneuroma, benign)  
 
 
 
 
 
 
 
 
 
 
	   5	  
The differentiation state of the tumor has some prognostic significance, but a more sophisticated 
histopathological classification has been developed to help predict outcome and select therapy. The 
generally accepted method is the International Neuroblastoma Staging System (INSS) (7) which 
subdivide Neuroblastoma into 5 different stages as follows:  
Stage 1 Localized tumor with grossly complete resection with or without microscopic residual 
disease; negative ipsilateral lymph nodes.  
Stage 2A Localized tumor with grossly incomplete resection; negative ipsilateral non adherent lymph 
nodes.  
Stage 2B Localized tumor with or without grossly complete resection with positive ipsilateral 
nonadherent lymph nodes; negative contralateral lymph nodes. 
Stage 3 Unresectable unilateral tumor infiltrating across the midline with or without regional lymph 
node involvement, or localized unilateral tumor with contralateral regional lymph node 
involvement, or Midline tumor with bilateral extension by infiltration (unresectable) or by lymph 
node involvement. 
Stage 4 Any primary tumor with dissemination to distant lymph nodes, bone, bone marrow, liver, 
skin or other organs (except as defined for stage 4S). 
Stage 4S Localized primary tumor (as defined for stages 1, 2A or 2B) with dissemination limited to 
skin, liver and bone marrow (limited to infants <1 year age). 
 
In a recent study, diagnostic biopsies from 240 neuroblastomas were analysed for genome 
sequencing revealing a low mutation rate in a small number of individual genes. The median 
frequency of mutation rate was 0.60 mutations per Mb, which is markedly lower than that found in 
adult solid tumors (8, 9).  
Constitutional chromosome abnormalities have already been reported in some neuroblastoma 
patients, but no consistent pattern has emerged as yet. Because of the majority of neuroblastomas 
occurs spontaneously, many genetic changes are already associated with these sporadic tumors. 
Among all, de-regulation of oncogenes expression, gain and/or loss of alleles and changes in cell 
ploidy have been shown to be critical in the development of sporadic neuroblastomas (7).  
Taken together, the multiplicity of several and heterogeneous initiating events proposes that 
neuroblastoma is a complicated genetic disease in which interconnection between different effects 
from multiple genetic alterations might be needed for tumourigenesis.  
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GENETIC ABNORMALITIES IN NEUROBLASTOMA 
 
Subsets of patients show a genetic predisposition to develop neuroblastoma following an autosomal-
dominant pattern of inheritance. 
The literature data suggest that almost 22% of all neuroblastomas could be the result of a germinal 
mutation (10). This hypothesis is fortified by several clinical observations showing that the median 
age at diagnosis of patients with familial neuroblastoma is reduced from 18 months to 9 months (7). 
Although some patients have a predisposition to develop the disease, most neuroblastomas occur 
sporadically (2). 
In spite of the fact that most tumors have a diploid karyotypes, low stages tumors are often 
hyperploid. Unfortunately, this aspect is not easy to assess since cells karyotyping assays are mostly 
unsuccessful (11). 
Another important and significant abnormality is amplification of DNA loci, which in 
neuroblastoma involves at 2p24 (N-Myc gene’s locus ) and also at 2p22, 12q13 (MDM2 gene), 
2p13, and 1p32 (MYCL gene) (12-15). 
Trisomy of 17q is one of the most recurrent genetic abnormalities in neuroblastoma (16). How 
genes mapping in this region are responsible for selective advantage is still largely unknown, though 
they have convincingly been proposed to have an anti-apoptotic role, with consequences for the 
survival rate (17). 
Activating mutations of RAS proto-oncogene are rare in neuroblastoma, however some studies have 
shown a possible correlation between high expression of HRAS with a lower stage disease and good 
prognosis. Activation of RAS proteins may result from activation of tyrosine kinase receptor, such as 
TRKA (18-20). Deletions of some chromosomes are common in neuroblastoma and generally 
correlate with different clinical stages (4). Loss of Heterozygosity 1p (LOH 1p, 30-35% of 
neuroblastomas) is strictly associated with N-Myc amplification and aggressive stage of tumor. 
Normally, and in case of N-Myc amplification, LOH 1p cause chromosomic deletions in DNA 
regions encoding for several important oncosoppresor genes like: CDH5, miR34a and KIF1β (21, 
22). 
On the other hand, deletions in 11q and 14q have not ever been found together with 1p and N-Myc 
genetic status (23). Notably, Loss of heterozygosity in 11q has been linked with event-free survival 
but only in patients that lack N-Myc amplification. Apparently the cause is that only few of these 
tumors have 11q loss and N-Myc amplification and the prognostic N-Myc value is dominant (6). 
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Among all genetic abnormalities, N-Myc amplification (20% of all neuroblastomas) is the most 
important biological feature of aggressive neuroblastomas. The average number of N-Myc genomic 
amplification is between 50 and 500 and because of the length of genomic region amplified (from 
100kb to 1Mb) other important genes and/or genomic elements are co-amplified together with N-
Myc gene (6). 
 
MYC FAMILY 
 
In 1980s a viral oncogene directly responsible in transformation induced by Rous Sarcoma Virus 
(RSV) and the human homologue c-Myc were discovered (24). This new human oncogene was 
thoroughly investigated and two other homologous genes were discovered: N-Myc and L-Myc (25, 
26). These three genes are characterized by a good degree of homology and are members of the Myc 
family.  
It is known that all the Myc family members are differentially expressed in distinct temporal patterns 
during embryonic development (27). c-Myc is highly expressed in most proliferating cells and is 
generally low or absent during quiescence. N-Myc, although present at low levels in many neonatal 
tissues, is highly expressed in pre-B cells, the kidney, the hindbrain and the intestine. In other tissues 
such as the telencephalon, retina, and intestine, N-Myc expression has been detected throughout 
differentiation stages whereas c-Myc is downregulated (28-30). 
During gastrulation, c-Myc is expressed at high level in extra embryonic tissues, whereas N-Myc 
expression is mostly detected in the expanding primitive streak and in other regions of the 
embryonic mesoderm; during the differentiation to epithelium N-Myc expression has been shown to 
be down-regulated (29).  
The L-Myc genic expression is detected in the developing kidney, lung and in both proliferative and 
differentiative areas of the brain and neural tube (31).  
The three Myc family members are transcription factors belonging to a subclass of the larger group 
of proteins sharing Basic-Region/Helix–Loop–Helix/Leucin-Zipper (BR/HLH/LZ) motif. 
Molecular phylogenetic studies on MYC family members have revealed large segments of moderate 
conservation that are marked by six regions of straight homology: five MYC-boxes and one 
BR/HLH/LZ (32, 33). 
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The general structural organization of proteins belonging to the MYC family (Figure 2) is similar for 
all members and consist of: 
- A large N-terminal portion including MYC-box I and II, involved in positive transcription 
regulation (TAD domain).  
- An internal segment including proline rich residues (PEST) as well as two conserved regions MYC-
box III and IV. 
- A C-terminal portion comprising the basic-Helix-Loop-Helix leucine zipper domain 
(BR/HLH/LZ).  
 
 
 
 
 
 
 
 
  
Figure 2: Structure of MYC family members (34). 
 
The N-terminal MYC TAD domain, comprising MYC-box I and II, fused to heterologous DNA 
Binding Domain (DBD), is sufficient for transcriptional activation and is also chiefly responsible for 
MYC Ubiquitin-mediated degradation (23). 
Several studies have demonstrated that MYC-box II is essential to promote, both in-vitro and in-
vivo, cellular transformation and to positive and/or negative regulating transcriptional events. The 
main importance of MYC-box II in transcriptional regulation of several targets genes is surely 
attributable to its role in binding of co-activators like: TRRAP, GCN5, BAF53, SL1, BIN1 and 
PML(35-37). 
In 2005 Herbst A. and collegues focused their attention on the “little studied” MYC-box III. 
Thanks to conditional expression of delta ER_c-MYC mutants in Rat1a mouse cell line, the critical 
role of MYC-box III in transcriptional repression activity of tumor related genes like P21, P15 and 
GADD45 was underlined (36). 
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          Figure 3: Heterodimer Myc-Max bound to consensus E-box DNA sequence (34).  
 
 
C-terminal segment of MYC factors is essential for heterodimerization with another small bHLH-
LZ protein named MAX. MYC-MAX heterodimer acts as a “core DNA-binding module” (Figure 3) 
recognizing consensus DNA sequence “CACGTG” also called “Enhancer-BOX” (E-box) (32, 34). 
 
THE MYC/MXD/MNT/MAX NETWORK AND THE TRANSCRIPTIONAL CONTROL OF CELL BEHAVIOR  
 
MYC members are incapables of forming homodimers and binds to specific DNA sequences. The 
primary partner for MYC transcriptional regulation activity is the small bHLH-LZ protein MAX 
(38).  
Unlike that of Myc genes, Max expression is ubiquitous and constitutive, and this 160 aminoacid 
protein is stable, resulting in Max levels that far exceed those of Myc (39). 
MAX is a bHLH-LZ transcription factor that lack all conserved MYC box domains and can both 
form homodimers and heterodimers capable of directly bind to E-box DNA consensus sequences. As 
well as with MYC factors, MAX can heterodimerize with other bHLH-LZ proteins of the MXD 
family (MXD1-4), MNT and MGA (37, 38).  
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MXD1 and MXD4 are generally expressed in differentiated cells, whereas Mxi1 (MXD2), Mad3 
(MXD3) and Mnt, like all Myc genes, are also expressed in proliferating cells. These findings give 
rise to the hypothesis by which the MYC/MXD/MNT/ MAX constitute a fine tuned homo and 
hetero dimerization network surrounding the small ubiquitously expressed bHLHLZ protein MAX.   
Overexpression experiments have suggested that MAX interacting proteins can antagonize the 
transcription regulatory activity of MYC family members. MAX homo- and/or hetero-dimerization 
with MXD and MNT result in repression of MYC-MAX activated gene targets. Transcriptional 
repression is establish by both MXDs and MNT by recruiting co-repressor complexes like N-CoR, 
Sin3a/Sin3b and the histone deacetylases 1 and 2 (Figure 4). The ability of MXD and MNT to 
physically interacts with Sin3a/Sin3b is allowed by an internal Sin3 Interaction Domain (SID) (18, 
19, 39, 40).  
Recent studies carried out using a negative Myc mutant called “MadMyc”, in which DNA binding 
and dimerization domain of Myc were fused with SID of MAD, have shown inhibition of cell 
proliferation and cell cycle arrest (41). 
  
 
 
 
 
 
 
 
 
 
 
Figure 4: Differences between transcriptional regulation by MYC-MAX heterodimer and MAD-MAX 
heterodimer at level of E-box DNA elements (19).  
 
Our understanding of the MYC/MXD/MNT/MAX network grew out of research on the MYC 
oncogene family. The first compelling idea about MYC was that its function drive cell growth and 
proliferation in response to a wide range of signals. Indeed, MYC genes are widely expressed during 
embryogenesis, and targeted deletions of c-MYC or N-Myc genes in mice lead to lethality in mid-
gestation embryos (37, 38). Moreover, there is a strong correlation between MYC expression and 
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proliferation (9, 18, 19, 39-41). In cells with activated MYC, G1 phase is often shortened as cells 
enter the cell cycle, and MYC is essential for G0/G1 to S phase progression (23, 42, 43).  
 
BIOLOGICAL FUNCTIONS OF MYC 
 
It is now clear that a wide range of growth factors, cytokines, and mitogens induce MYC expression 
in many cellular backgrounds (11, 33). Both transcriptional and/or post-transcriptional regulation 
can determine an increase in endogenous MYC and appears to occur as an immediate early response 
(about 2 hours) to most mitogenic factors (44).  
On the other hand, anti-proliferative signals must down regulate MYC expression, constituting a 
signal for cells to exit the cell cycle and undergo differentiation. Moreover, the induction of MXD 
family members, in response to different cues, is another important point of regulation to allow cell 
differentiation (20, 39, 42).  
In the case of specific lineage commitment, an increase of MYC, determining boost of proliferation, 
also constitutes physiological event that is essential cell differentiation. Clearly, these data strongly 
suggest that MYC is a nexus for multiple growth signal response pathways. Therefore both MYC 
expression and activity are tightly regulated in non-transformed cells and finely tuned to quickly 
respond to proliferative cues from the extracellular milieu (14, 45).  
The ability of MYC overexpressing cells to facilitate proliferation and inhibit terminal differentiation 
perfectly fits with different genetic rearrangements involving MYC family genes in several types of 
cancer, such as genomic amplification of N-Myc in almost 25% of neuroblastoma tumors (6).  
Indeed, many of the genomic alterations in the MYC gene result in increased MYC mRNA levels 
through increased transcription initiation, decreased transcription attenuation, and augmented 
stability of the MYC mRNA (20, 41). Moreover, many tumor-related mutations in Myc result in 
significant protein stabilization (23, 43).  
One of the most striking findings of the past years was the discovery of the important role of 
enhanced expression of Myc proteins in almost every aspect of tumor cell biology (33). Whereas the 
ability of Myc to drive unrestricted cell proliferation and to inhibit cell differentiation has long been 
recognized, many studies have already underlined that deregulated Myc expression can drive cell 
growth and vasculogenesis, reduce cell adhesion and promote metastasis and genomic instability. 
Conversely, the loss of Myc proteins inhibits cell proliferation and cell growth and also accelerate 
differentiation, increases cell adhesion and leads to an excessive DNA damage response (33).  
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In the last 15 years, in several neuroblastoma cell lines, there were analysed possible interconnections 
between N-Myc level and miRNA expression profile, stressing that N-Myc can both activate and 
repress many of non coding RNAs like mir 17-92 cluster, Mir 9 and Mir-421 (46). 
This findings reflects the surprisingly high number of target genes regulated by Myc, as emerged in 
large-scale analyses of MYC-regulated genes. Indeed, in normal cells, Myc protein appear to 
integrate environmental signals in order to modulate a wide, and sometimes opposite, group of 
biological functions including proliferation, growth, apoptosis, energy metabolism and 
differentiation (45).  
 
MYC AS AN ACTIVATOR 
 
MYC factors, as already indicated,  must heterodimerize with the small b-HLH-BZ protein MAX to 
directly bind DNA. MYC-MAX complex have relatively weak transactivation activity both at 
endogenous level and in transient assays (47). Recently published transcriptomic analysis have 
underlined the weak ability of Myc proteins to activate the majority of target genes (generally 
ranging from 3- to 10-fold transactivation) (48). 
In general, the transactivation domain of Myc (TAD) recruits the basal transcription machinery 
either directly or indirectly, thanks to different protein complexes formed with several accessory 
factors. The most relevant model of MYC-mediated transcription activation postulates that MYC 
increases local histone acetylation in the promoter regions (33). In this connection, MYC binds to 
histone acetyltransferase complexes including TRRAP (transformation/transcription-domain- 
associated protein) and either general control of amino-acid-synthesis protein-5 (GCN5) or TIP60, 
which preferentially acetylate histones H3 or H4, respectively (49, 50). Myc can also binds to the 
p300/CBP (CREB-binding protein) acetyltransferase (51, 52). 
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Figure 5: Mechanisms of MYC-induced transcription. Myc recruits histone acetyltransferases, which promote 
localized modification of chromatin through nucleosomes acetylation (52). 
 
The action of acetyltransferase complexes, recruited by MYC factors, determine positive signal for 
transcription activation. The acetylated and more relaxed chromatin status provides docking sites for 
acetyl-histone-binding proteins, including GCN5 and the SWI/SNF chromatin-remodelling 
complex, both correlating with increased transcription levels (Figure 5). Moreover, acetylated 
euchromatic DNA regions would permit subsequent binding of constitutive and general 
transcription factors that allow RNA polymerase II promoter docking (52, 53). 
The recruitment of histone modifiers by transcription regulators is accepted to be a major 
mechanism of transactivation, shared by many other transcription factors, like: TCF (T-cell factor), 
E2F, the tumor suppressor TP53 and Gal4 (54).  
In the last decade genome-wide expression analysis, performed by many groups and in many cellular 
backgrounds, has revealed a staggering number of MYC target genes, around 10-22% of all genes in 
most models. Chip-seq analysis have shown higher Myc affinity for cell cycle related promoters than 
through all Myc-related promoters (41). 
Among others, target genes include the Cyclin-Dependent Kinase-4 (CDK4), the Cdc25A 
phosphatase which activates CDKs, cyclin D2, CKN1A(p21), p27 and the E2F family. E2F gene 
family encodes for transcription factors critical for G1-S progression and in quiescent cells E2F-/- 
Myc fails to induce G1-S progression (41, 55). Recently, Myc has been shown to promote oxidative 
phosphorylation as well as glycolysis through coordinate transcriptional control of the mitochondrial 
metabolic network (56). 
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In addition to cell cycle control and metabolic target genes, Myc has been found to activate several 
essential genes involved in many biological functions like control of cell size and growth, including 
those encoding ribosomal proteins, translation factors, and metabolic enzymes (57-60). These 
findings stress the role of MYC factors in recruitment of co-activator complexes into regulatory 
regions contacted by RNA polymerase I and III (61-64). 
MYC regulation can also occurs at the level of transcriptional elongation and not just at 
transcriptional initiation. The C-terminal domain (CTD) of RNA pol II undergoes to cycling 
phosphorylation and de-phosphorylation during transcription. Hypo-phosphorylated form of CTD 
determines RNA pol II recruitment to promoters, while high level of phosphorylation occurs during 
initiation and elongation steps. Sub-sequent de-phosphorylation allow RNA pol II recycling for 
another round of transcription (65). RNA pol II has been found to pause on most promoters after 
transcribing approximately 20–40 bases. This model fits well with the finding that Myc stimulates 
the release of paused RNA pol II from the promoter and stimulates subsequent transcriptional 
elongation (66). Myc transactivation domain (TAD) binds directly to CTD kinases determining an 
increase in RNA pol II phosphorylation and elongation. Myc induction occurs globally throughout 
the nucleus and it can be detected in the total cellular pool of RNA pol II rather than simply at 
MYC target-gene promoters (66, 67). 
Moreover, Myc factors are also involved in control of mRNA stability, by promoting 5' methylation 
of guanine or 'cap', which is an essential step for protein-coding gene expression. This transcription-
independent activity underlines the critical role of MYC in transcription and post-transcription 
regulation in both normal and tumor cells (68, 69). 
Along with transcription, the most important nuclear process is DNA replication. The genome must 
be faithfully replicated each cell cycle and the chromosomes must be segregated to the daughter cells. 
Disruption of any step in this process, such as a stalled replication fork or DNA damage occurring 
during S phase, activates checkpoints that halting the cell cycle until the lesion can be repaired. 
Failure to correct this damage leads to a mutation and/or genomic instability. In fact, it has been 
hypothesized that high MYC expression correlate with genomic instability because of the indirect 
consequence of MYC mediated de-regulation in normal transcriptional activity (70, 71).  
A recent study have described a direct, non-transcriptional, role for MYC in the initiation of DNA 
replication. Myc has been found to bind numerous components of the pre-replicative complex, and 
localize to early sites of DNA replication. These observations have suggested that MYC might 
directly control the initiation of S phase and this effect on genomic instability might not depend on 
the transcriptional induction of S-phase-promoting genes. Furthermore much excitement has been 
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generated in the past few years about the role of noncoding regulatory RNAs. The first oncogenic 
polycistronic microRNA is shown to be regulated by MYC (42). 
Taken together, these findings raise the question: are MYC factors just like traditional transcription 
factors or are they guardians of cell metabolism?  
Surely the transcription activity is the main known function of the oncogenic MYC protein. 
Apparently, a disconnection seems to exist between MYC’s dramatic effects on multiple cellular 
functions and its biological and molecular characterization as a relatively weak transcriptional 
activator. Indeed, the notion that Myc is a general chromatin regulator is nonetheless consistent with 
several recent observations concerning MYC function. First, independent expression microarray 
analysis have collectively identified a large group of genes regulated by Myc. Second, chromatin-IP 
experiments directly assessing Myc binding to thousands of sites throughout the genome 
encompassing approximately 15% of genes as well as intergenic regions (48, 66, 72, 73). Potentially, 
therefore, Myc can regulates a significant percentage of all genes in an organism.  
The number of in-vivo binding sites exceeds the number of Myc molecules in proliferating cells, 
indicating that each site is bound by Myc only temporarily. Most probably, therefore, transcriptional 
regulation by Myc occurs by a 'hit-and-run' mechanism whereby the relatively brief binding of Myc 
triggers longer-lasting changes in the chromatin organization at the bound loci (45). 
Many recent evidences underline the role of N-Myc in the global regulation of human genome 
euchromatin, including that of intergenic regions. Strikingly, N-Myc maintains 90% to 95% of total 
H3K9 acetylated and H3K4Me marks, with enhancer-like function, in human several 
neuroblastoma cell lines (74). Furthermore Myc may regulate chromatin at a distance so that Myc 
binding at one location can influence chromatin at another site through an high order chromatin 
structure (75). 
Intriguingly intergenic binding sites for MYC are not enriched for E-boxes. Although E-box 
independent binding has been reported and may be fairly widespread, such binding may be of 
particular importance for Myc intergenic function (70). 
Furthermore, Myc has been shown to possess another feature outside the context of E-boxes: 
surprisingly Myc can also act as well as a transcriptional repressor at certain target promoters 
consistent with the wide distribution of MYC along the genome(see below) (76-78).  
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MYC AS A REPRESSOR 
 
One of the first finding highlighting the idea that MYC can also act as a transcriptional repressor 
derived from studies published in the 1980s, suggesting that MYC participates in a negative 
feedback loop (79, 80). Genome-wide analyses demonstrate that MYC represses at least as many 
targets as it activates, further emphasizing the role of repression in MYC function, including 
transformation (45, 81). 
No simple consensus sequences for transcriptional repression by Myc has emerged, this finding 
opens up the possibility that transcriptional repression is a simply indirect consequence of the altered 
physiological (e.g., transformed) state of a cell induced by Myc (82, 83). 
In the last 10 years a lot of studies have been carried out to fully understand the mechanism of MYC 
repression. Many investigators have exploited a chimeric MYC-MAD protein to better define MYC 
transcriptional activity, but this chimera cannot fully recover the transformation potential of wild-
type MYC factors in-vivo; for example, they are unable to immortalize primary mouse embryo 
fibroblasts and to induce apoptosis in immortalized cells and are impaired in rescuing the 
proliferation defect of c-myc -/- fibroblasts (84).  
These important findings, together with several other illuminating researches, support the hypothesis 
that the oncogenic potential of MYC factors is fulfilled by both activation and repression activity.  
The actual model of MYC repression is based on the indirect DNA binding on cis-genomic 
elements, interacting directly with other transcription regulators bound to DNA. The repressed 
genes, like induced genes, fall into multiple functional classes. Among all, genes encoding for factors 
selectively expressed in quiescent cells or involved in inhibit cell proliferation. This group 
encompasses the cell cycle inhibitors p21 (85-88), p27kipl (89, 90), pl5ink4b (91, 92), pl8ink4c 
(93), and p57kip2 (94), as well as the differentiation-inducing proteins C/EBP-a (95), the growth-
arrest proteins gas1 and gas2 (96), the growth arrest and DNA damage proteins gadd34, gadd45, 
gadd153 (70, 97, 98), and the Myc-antagonist Mad4 (99). Myc can also down regulate genes 
encoding for proteins deeply involved in cell adhesion, including a large number of integrins: these 
genes include those encoding cell surface proteins such as the class I HLA molecules in melanoma 
cells, the α3 β1 integrin in neuroblastomas, and the LFA-1 (αL β2 integrin) cell adhesion protein in 
transformed B cells as well (100). Altered cell adhesion is a hallmark of many Myc-transformed cells 
and has been observed in different cell types (101). Metabolic pathways such as thrombospondin 
and H-ferritin are also affected by Myc mediated repression (102, 103). Suppression of 
thrombospondin plays a causative role in the induction of angiogenesis by Myc. In the last 10 years 
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ABCC3 has been identified as MYC repressed gene, it encode for an important multi-drug resistance 
protein involved in chemo-resistance and also in cell migration (104). Therefore, Myc-mediated 
gene repression in the control of cellular differentiation and in the response to growth arrest signals 
makes a significant contribute to the phenotype of MYC-transformed cells. The basic mechanism 
underlying MYC's activation of transcription is well understood, but the way in which MYC 
negatively regulates or represses transcription is far less understood (81).                                            
A number of Myc-repressed targets contain a subclass of initiator elements (INRs; consensus, 
YYCAYYYYY, where Y is a pyrimidine base), which are usually, but not invariably, present at 
TATA-less promoters. Inr elements are recognized by TFIID as well as by a number of regulatory 
proteins, such as the transcription initiation factor TFII-I, YY-1, and the Myc interacting zinc-finger 
protein 1 (Miz-1). Interestingly, the last three proteins have been reported to associate with the C-
terminal BR/HLH/LZ region of Myc (101). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Mechanisms of transcriptional repression by c-Myc. (A) Inr-dependent mechanism of MYC 
repression. Myc–Max heterodimers bind to the Inr element and associate with Miz-1 or other TFs, thus 
interfering with their activities. (B) c-Myc represses target genes transcription by Sp1-dependent mechanism. 
c-Myc interacts with the Sp1 transcription factor (1) or with the Smad–Sp1 complex (2) via the c-Myc 
central region and inhibits Sp1 transcriptional activity. This mechanism does not require DNA binding or 
interaction with the c-Myc partner Max (105). 
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MYC mediated repression of p15 and CKN1A(p21) promoters has been thoroughly described and 
could be perceived as prototypical for MYC dependent transcriptional repression of growth arrest 
genes. 
There are two main independent mechanisms of MYC mediates repression. The first is based on the 
ability of MYC-MAX heterodimer to bind the zinc-finger protein Miz-1 and this complex is now 
capable of binding to transcriptional initiator elements (Inr) (figure 6, A) (101). Miz1 contains 13 
zinc fingers and, at its amino-terminus, carries a BTB/POZ-domain, which is a protein-protein 
interaction domain found in multiple zinc-finger proteins. Miz1 binds to the 'outside' of the helix–
loop–helix domain of Myc, but does not interact with Max, Mad or Mnt proteins (106, 107). The 
second mechanism by which MYC-MAX represses transcription implies interaction with SMAD 2/3 
proteins and consequent complex formation with another TF called Sp1 (figure 6, B2) (108). 
In case of p15 transcriptional regulation, Miz-1 acts as positive factor but the interaction with MYC-
MAX inhibit the Miz-1 mediated p300 recruitment at Inr element. Conversely, MYC-MAX can 
carry out p15 repression in Inr independent manner. In fact, p15 gene activation can be establish by 
positive transcription complex formed by several combination of SMAD2, SMAD3 and SMAD4 
with Sp1. MYC-MAX can interact with SMAD2/3 to form a larger, inactive but more stable 
complex formed by MYC-MAX/SMAD2/3/Sp1 (101).   
Several published data have revealed both c-Myc and N-Myc repression activity on CKN1A(p21) 
gene transcription. MYC factors do not directly bind to DNA but they form complexes with Sp1 
factors determining, as already mentioned for p15 repression, the absence of transcriptional 
activation (86). 
On the other hand, there are some genes repressed by MYC through a mechanism that does not 
involve the Max protein (109, 110).  
In 2005 Brenner and colleagues demonstrated recruitment of DNA methyltransferase, DNMT3a, 
by c-Myc to CKN1A(p21) promoter in a MAX independent complex composed by c-Myc and Miz-
1. This finding disclosed the important interconnection between c-Myc repression activity and 
DNA methylation (106, 107). Since DNMT3a is complexed with histone deacetylases enzymes, its 
recruitment by Myc might lead to local histone deacetylation and inhibition of transcription (107). 
Recruitment of DNMT3a by Myc is an attractive mechanism for repression, since it might provide 
an explanation of the aberrant DNA methylation of some tumor suppressor genes that is observed in 
some human tumors. 
Recent studies have shown that not all genes repressed by Myc are silenced by the same mechanism. 
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Another finding that reinforce the idea that there exist multiple and variegates MYC repressive 
pathways is the discovery of N-Myc-PRC2 (via N-Myc and EZH2 physically interaction) repressive 
complex on the promoter of the tumor suppressor gene CLU in neuroblastoma cellular background 
(111).     
All these data clearly support the notion that several pathways of repression exist. Finally, the present 
model is that Myc interacts with transcriptional activators that are bound directly to DNA through 
enhancer or initiator elements either cooperating with MAX or not. These multi-protein complexes 
are thought to inhibit recruitment of co-activators, facilitating the negative and oncogenic activity of 
co-repressors like DNA methyltransferases, histone methyltransferases and deacetylases (105, 112).  
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EPIGENETICS, AN OVERVIEW 
 
The definition of epigenetic, coined by Conrad Waddington, is: “An epigenetic trait is a stably 
heritable phenotype resulting from changes in a chromosome without alterations in the DNA 
sequence” (113). 
Shelley L. Berger and colleagues, proposed three categories of signals that trigger different 
establishment of stably heritable epigenetic states (Figure 7): 
- “Epigenator,’’ which emanates from the environment and triggers an intracellular pathway; 
- ‘‘Epigenetic Initiator’’ signal, which responds to the Epigenator and is necessary to define the 
precise location of the epigenetic chromatin environment; 
- ‘‘Epigenetic Maintainer’’ signal, which sustains the chromatin environment in the first	  and 
subsequent generations (114).  
 
 
 
 
 
 
 
 
 
 
 
     
      Figure 7: The epigenetic pathway. 
 
The fine tuned DNA organization inside the nucleus is an essential aspect of eukaryotic cell life. 
Chromatin is the macromolecular complex composed by DNA, RNA and proteins, determining 
genomic DNA condensation inside the nucleus. Mainly, there are four chromatin packaging degrees 
ranging from 11nm DNA fibers to 700nm interphasic DNA domains (Figure 8) (114, 115). 
The plastic, finely tuned and rapid exchange of different levels of genomic DNA condensation is a 
critical step for almost all the biological issues linked to DNA. 
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Every 147bp, DNA is wrapped around an octameric protein complex, the nucleosome. Five 
different proteins (Histones) compose this functional unit: H2A, H2B, H3, H4 and H1. The 
nucleosome structure is globular except for the histone n-terminal “tails”, which are unstructured. As 
mentioned above, chromatin condensation is an essential regulating “tool” of many important 
biological aspects like DNA transcription (114, 115). 
The nucleosome is also target of several dynamic post-translational modifications of histone n-tails 
which determine the “fate” of transcriptional activity of all the genes encoded by genomic DNA 
(116).	   Indeed, histone modifications are crucial to dictate different genomic packaging levels inside 
the nucleus (Figure 8). These changes in DNA condensation ranging from heterochromatin, highly 
condensed and transcriptionally repressed or silenced to a more accessible status of DNA defined as 
euchromatin in which genomic regions are tightly packaged and are transcriptionally active (114-
117). 
 
 
 
 
 
 
 
 
 
 
 
                   Figure 8: Graphical representation of different chromatin condensation degrees (36). 
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DNA METHYLATION AND HISTONE MODIFICATIONS 
 
Among all the chromatin modifications, we can distinguish direct DNA modification, including 5-
methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-
carboxycytosine (5caC) and n-tail covalent nucleosome modifications such as: acetylation, 
methylation, sumoylation, ubiquitination and phosphorylation (116-118).  
DNA methylation is the covalent addition of a methyl group (CH3) to the C5 position of cytosine 
in CpG dinucleotides. Genomic regions containing multiple stretches of  CpG dinucleotides termed 
as “CpG islands” and they are often associated with promoters elements (119).  
In mammals somatic cells, methylated cytosines account for 1% of total DNA bases, but only 10% 
of these are located in CpG islands (120). Unlike the dispersed CpG elements, those in CpG islands 
are more resistant to methylation events (119, 121). 
Cytosines are methylated by the DNA methyltransferase machinery composed of two subunits: the 
DNA methyltransferase (DNMTs) and the methyl CpG binding protein (MBDs). Until now there 
no evidences have been found about activity responsible for DNA de-methylation (119). 
In 1983 the clear correlation was first demonstrated between hypomethylation and genomic 
instability of cancer cells. In the last 20 years many studies have corroborated the hypothesis that loss 
of genomic methylation is an early event in many type of cancer (122). 
Many genes involved in cell-cycle regulation, tumour cell invasion, DNA repair, chromatin 
remodelling, cell signalling, transcription and apoptosis are known to become aberrantly 
hypermethylated and silenced in many tumour type. Probably the hypermethylation status increases 
genetic instability, allowing cancer cells to acquire advantageous genetic changes and to proliferate 
and to metastasize (122, 123). 
Ever since Allfrey's studies in the early 1960s, we have known that histones can be post-
translationally modified by a large number of different histone post-translational modifications 
(PTMs) (124). There are at least eight distinct types of modifications found on histones (Table 1). 
The dynamic and heterogeneous network of histone modifications determine the transcriptional 
“fate” of all the genes encoded by genomic DNA (125). 
Extra complexity comes partly from the fact that methylation at lysines or arginines may be one of 
three different forms: mono-, di-, or trimethyl for lysines and mono- or di- (asymmetric or 
symmetric) for arginines (116).  
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a protein has to be digested before such analysis can take
place limits its potential. New methodology that uses
a top-down proteomics approach (identify protein first
and digest subsequently) gives promise that we may, in
the future, look at the intact modification pattern of differ-
ent histones in a given nucleosome (Macek et al., 2006).
Once global analysis of all histone modifications is
done, a prediction would be that every single nucleosome
would be found to bemodified in someway. This picture is
of course very static. The truth is that modifications on his-
tones are dynamic and rapidly changing. Acetylation,
methylation, phosphorylation, and deimination can
appear and disappear on chromatin within minutes of
stimulus arriving at the cell surface. Thus examining bulk
histones under one specific set of conditions (with either
antibodies or mass spectrometry) will identify only a
proportion of the possible modifications.
There are also problems of detection that are specific
for antibodies. Firstly, there are the obvious issues of
specificity. These are difficult to avoid as there are no
true controls for modifications in mammalian cells (unlike
yeast) where it is impossible to mutate the residue to
make sure reactivity is lost. In addition, an adjacent
modification may disrupt the binding of the antibody or
a protein may occlude its recognition, both of which may
give a false reading. Similarly, there are problems of
detection that are specific to mass spectrometry. Peptide
coverage is not equivalent for all parts of the histone and
this reduces the sensitivity of detection in these regions.
These facts undoubtedly contribute to our underestima-
tion of the extent of modifications present on histones.
We assume that each individual modification on his-
tones leads to a biological consequence. However proof
of a consequence is not always easy to provide and is
often based on a correlation: a modification appears on
a gene under certain conditions (e.g., when it is tran-
scribed) and disappears when that state is reversed
(e.g., when the gene is silent). Proving causality for a
modification involves showing that the catalytic activity
of the enzyme that mediates the modification is necessary
for the biological response. However we know that many
of the histone-modifying enzymes have other nonhistone
substrates. So the response may be going through
another unidentified protein substrate. Furthermore, there
may be signaling redundancy such that more than one
enzyme may be capable of modifying a specific site. In
this case, the effects of inactivating one enzyme may be
masked by an upregulation in the activity of a second
distinct but related enzyme. Showing that mutation of
the modified residue gives the same output as mutating
the enzyme is a second stringent test. However, this is
not possible in humans due to many histone genes
present in the genome, but it is possible in yeast.
So the truth is that we have ‘‘levels of confidence’’
regarding the causative nature of different modifications
depending on how far the analysis has gone to prove the
issue. We also have to be realistic and accept that, how-
ever far we go in proving that a histone modification is
causative, we can never exclude the possibility that
modification of other substrates by the same enzyme
will play a parallel role in the biological response being
monitored. The many other nonhistone substrates of
chromatin-modifying enzymes are not covered in this
Review.
Histone-Modifying Enzymes
The identification of the enzymes that direct modification
has been the focus of intense activity over the last 10 years
(Table 2). Enzymes have been identified for acetylation
(Sterner and Berger, 2000), methylation (Zhang and Rein-
berg, 2006), phosphorylation (Nowak and Corces, 2004),
ubiquitination (Shilatifard, 2006), sumoylation (Nathan
et al., 2006), ADP-ribosylation (Hassa et al., 2006), deimi-
nation (Cuthbert et al., 2004; Wang et al., 2004b), and pro-
line isomerization (Nelson et al., 2006).
Most modifications have been found to be dynamic,
and enzymes that remove the modification have been
identified. One major exception is methylation of
arginines: although they are thought to be dynamic, a
demethylating activity has not yet been found. Instead
Table 1. Different Classes of Modifications Identified on Histones
Chromatin Modifications Residues Modified Functions Regulated
Acetylation K-ac Transcription, Repair, Replication, Condensation
Methylation (lysines) K-me1 K-me2 K-me3 Transcription, Repair
Methylation (arginines) R-me1 R-me2a R-me2s Transcription
Phosphorylation S-ph T-ph Transcription, Repair, Condensation
Ubiquitylation K-ub Transcription, Repair
Sumoylation K-su Transcription
ADP ribosylation E-ar Transcription
Deimination R > Cit Transcription
Proline Isomerization P-cis > P-trans Transcription
Overview of different classes of modification identified on histones. The functions that have been associatedwith eachmodification
are shown. Each modification is discussed in detail in the text under the heading of the function it regulates.
694 Cell 128, 693–705, February 23, 2007 ª2007 Elsevier Inc.
 
 
 
 
 
 
 
Table 1: Overview of different classes of modification identified on histones (114). 
 
The combinatorial complexity of all the different histone modifications that can occur at the same 
time in the same nucleosome had always lead to several hypothes s ttempting to define “the histo e 
code” which actually is not fully understood (126). The histone code is read and construe by the 
n -histone protei s and multiprotein complexes at for  the tra scriptio -activating and/or -
repressing molecular machinery. Moreover, different chromatin binding proteins can be recruited by 
specific n-tail histone markers, but the simultaneous existence of two or more marks in the same 
nucleosome can lead to a ifferent scenario (126-128).    
Chromatin-regulating proteins can be divided into three main groups (Figure 9): 
 - “Epigenetic writer ” that directly modify specific N-tail residues; 
- “Epigenetic readers” that bind specifically to a type of covalently modified amino acid; 
- “Epigenetic erasers” that remove and/or convert distinct N-tail covalent modifications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Figure 9: Graphical representation of Chromatin binding proteins: Writers, readers and erasers (129). 
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In the last decade the already quirky network of histone writers and erasers has been complicated by 
the discovery of many modifiers able to methylate and demethylate specific residues of protein 
factors involved in transcription regulation. These modification also significantly affect the ability of 
transcription factors to form the protein complexes required to activate and/or to repress 
transcription of specific genes (128, 130). 
N-tail histone acetylation is the most common histone marker of opened chromatin and it occurs 
exclusively on lysine residues of histone H3 and H4. N-Acetylation of positively charged lysines 
determines an electrostatic neutralization, because of its negative charge. The effect of this change in 
net positive charged of histone determines an important loss of electrostatic interaction between 
nucleosome and DNA leading to a more relaxed and accessible chromatin status (124, 125). 
In 1964 Allfrey et al. first demonstrated the highly dynamic and finely regulated balance between 
histone acetylation and de-acetylation of chromatin. The plastic balance between histone acetylation 
and de-acetylation is respectively controlled by histone acetyltransferases (HATs) and histone 
deacetylases (HDACs). HATs, also known as K-acetyltransferases, catalyze the addition of acetyl 
groups to histone lysines using acetyl coenzyme A as cofactor. GCN5, p300/CBP, and MYST 
families composed the three main groups of HATs (51, 53). Just as HATs are a diverse set of 
enzymes, the multi-protein complexes in which they reside also vary in subunits composition. The 
considerable combinations of these accessory subunits lead to several unique features of each HAT 
complex. For example, some subunits have conserved domains that cooperate to recruit the HAT to 
the appropriate location in the genome; these include bromodomains, chromodomains, WD40 
repeats, Tudor domains and PHD finger (54, 131). 
Unlike positive transcriptional HATs activity, Histone DeACetylases (HDACs) led to repressed 
chromatin because of the increase in electrostatic interaction between nucleosomes and wrapped 
DNA. Until now, eighteen distinct human HDACs have discovered and grouped into four classes. 
Class I HDACs (HDAC1, -2, -3, and -8) are predominantly nuclear proteins and ubiquitously 
expressed in most tissues and cell lines. Class II HDACs can be subdivided into two subclasses, IIa 
(HDAC4, -5, -7 and -9 and its splice variant MITR) and IIb (HDAC6 and HDAC10), based on 
the protein sequence homology and domain organization. Class IIa HDACs have one catalytic 
domain and a long amino-terminal adaptor domain, while class IIb HDACs contain two catalytic 
domains. Class III HDACs, known as sirtuins, do not contain zinc and their activity requires 
nicotinamide adenine dinucleotide (NAD+). Class IV HDACs include only HDAC 11, a relatively 
newly discovered protein, which resembles class I HDACs (128, 132). 
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HATs and HDACs complexes have been shown to play a critical role in carcinogenesis, trough 
either inappropriate activation or repression of target gene activity (53, 125, 133). 
As already discussed, HATs complexes are co-activators of many TFs like MYC family oncoproteins. 
The role of HATs complexes in cancer, especially for p300 is not well understood, probably because 
its activity depends on different tumor backgrounds (134). p300 has been recognized as a potential 
anti-cancer drug target because its gene was found altered in most colon cancer cell lines and in some 
primary tumors (135, 136).  
p300 is also a target of viral oncoproteins, it can be fused to MLL in leukaemia and two missense 
mutations were found in epithelial malignancies (137). Conversely to its supposed oncosoppressor 
function, in prostate cancer p300 was found to have to a clearly oncogenic potential (134). 
HDACs have been intensely studied for their involvement in mediating the function of oncogenic 
translocation products in specific forms of leukaemia and lymphoma. For example, in acute 
promyelocytic leukaemia (APL), PML–RARα, represses transcription by associating with a 
corepressor complex that contains HDAC activity. In non-Hodgkin’s lymphoma, the transcriptional 
repressor LAZ3/BCL6 (lymphoma-associated zinc finger-3/B cell lymphoma 6) is strongly 
overexpressed and associated with aberrant transcriptional repression through recruitment of 
HDACs, leading to lymphoid oncogenic transformation (128).  
Another histone modification that leads to a change in the electrostatic balance between 
nucleosomes and DNA is the phosphorylation of serine, threonine and tyrosine residues on histone 
N-tails (138). 
The exact mechanism by which histone phosphorylation affects gene expression is not well 
understood; it is thought that, similarly to N-acetylation, the addition of phosphate group 
(negatively charged) to histone N-tails may interfere in the electrostatic interaction between 
nucleosomes and DNA. Like N-acetylation of histone N-tails, phosphorylation probably increases 
the accessibility of DNA to nuclear factors (138).   
Less is known regarding the roles of histone phosphatases. Certainly, given the extremely rapid 
turnover of specific histone phosphorylations, there must be high phosphatase activity within the 
nucleus. We know, e.g., that the PP1 phosphatase works antagonistically to Aurora B, the kinase 
that lays down genome-wide H3S10ph and H3S28ph at mitosis (124, 139). 
For the majority of kinases it is not yet clear how they are accurately recruited to their sites of action 
on chromatin. The mammalian MAPK1 enzyme possesses an intrinsic DNA-binding domain with 
which it is tethered to the DNA. Alternatively, histone kinases recruitment may require association 
with a chromatin bound factor before it directly contacts DNA to stabilize the overall interaction. 
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Even though the majority of histone phosphorylation sites lie within the N-terminal tails, there are 
examples of phosphorilation sites within the core histone region. For example, it was determined 
that the non-receptor tyrosine kinase JAK2 is responsible of H3Y41 phosphorylation (124, 140). 
Histones H1, H2A, H2B, H3, and H4 are all phosphorylated at multiple residues, but the most 
studied are so far the phosphorylations of histone H3. Phosphorylation reaction is catalysed by many  
distinct kinases that are mostly specific for individual histone residues (139). 
A huge number of studies have underlined the important role of H3S10 phosphorylation in positive 
gene regulation. This histone modification can be deposited by various kinases in relation to the 
biological context. Phosphorylation of H3S10 by mitogen and stress-activated protein kinases 1 and 
2 (MSK1 and MSK2) as well as RSK2 kinase has been shown to play a role in the activation of 
mitogen-stimulated immediate-early response genes,  such as c-fos and c-jun (139, 141, 142).  
Furthermore, Pim1 kinase catalyses H3S10 phosphorylation at the E-boxes in Myc target genes, 
contributing to their transcriptional activation after growth factor stimulation (139). While histone 
acetylation and phosphorylation balance can deeply change the net charge of nucleosomes, 
methylation is a chemical modification that does not alter electrostatic interaction between 
nucleosomes and DNA. As already mentioned above, mono-, di- or tri-methylation of histone N-
tails can occur on lysine, arginine and histidine residues (143). Methyltransferase activity lies with 
the catalytic ability to add methylic groups from S-Adenosyl methionine to specific aminoacid 
residues K, R and H. There are three main families of methyltransferases based on protein domains 
homology: Set1, DOT-1 like and PRMT (144). 
Methylation of H3K4, H3K36 and H3K79 are strongly associated with euchromatic regions, while 
methylation on H3K9, H3K27 and H4K20 is often found on repressed heterochromatin regions. 
Specifically, di- or tri- methylation of H3K4 are strictly associated with Trascriptional Start Site 
(TSS) DNA regions, whereas H3K4Me is closed linked with enhancer elements of active genes. 
While mono-methylation of H3K9 is often associated with active transcription, H3K9Me3 is a 
marker of transcription repression (114). 
Several scientific reports have already discussed the important interconnection between nucleosome 
methylation pattern and carcinogenesis in many tumor backgrounds. 
EZH2, together with SUZ12 and EED, forms the polycomb repressive complex 2 (PRC2), which is 
responsible for tri-methylation of H3K27. In cancer, EZH2 is one of the widely studied 
methyltransferase because of its clear relationship with many type of tumors like breast, prostate and 
lymphoma (130). As already highlighted for some HAT proteins several mehtyltransferases and 
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HDACs to cannot be absolutely classified as oncosoppresor or oncogene: it depends on the cellular 
background in which they act (144). 
 
MYC FACTORS AND HISTONE MODIFIERS IN CO-ACTIVATOR AND CO-REPRESSIVE COMPLEXES 
 
In 2014 Susanne Walz et al. performed RNA and ChIP seq analyses on U2OS and Hela cell lines 
respectively in a condition of doxycycline c-Myc induction and c-Myc silencing by Sh-RNA 
techniques. Both c-Myc activation and silencing revealed almost 30,000 MYC binding sites, and 
more than 200 up- and 100 down-regulated genes. Consistently, a linear support vector machine 
algorithm based on the set of MYC-regulated genes correctly classified 37 of 38 neuroblastomas as 
harbouring a single copy or amplified N-Myc gene. The most important finding that was suggested 
by Susanne Walz and colleagues is the correlation between high c-myc level and the occupancy of 
low affinity non-consensus E-box (CANNTG) sites. Conversely, change in c-myc levels did not 
affect occupancy in high affinity consensus E-box sequences (CACGTG) (81). 
These findings strongly suggest that the dynamic role of both c-Myc and N-Myc determines a 
profound change in the transcription profile of different tumors. Accordingly, MYC factors are 
widely studied in relation with different cis-elements in the whole cell genome and with 
heterogeneous multiprotein complexes composed by different histone modifiers.  
As already underlined before, protein-protein interactions may modulate MYC's transcriptional 
regulatory ability and therefore its potential for oncogenicity. A variety of proteins that interact with 
both c-Myc and N-Myc have been identified. Few of these have been shown to be directly recruited 
by MYC factors and to mediate the transactivating functions of MYC (78).  
One of the most widely studied MYC co-activator “partner” is the transactivation/transformation-
associated protein (TRRAP), which, together with several histone acetyltransferases (HATs), stably 
associated with TRRAP and the positive transcription elongation factor b (PTEFb), form large 
multiprotein complexes (145). Accordingly, it was reported that dominant-negative TRRAP genes 
or antisense TRRAP RNA can blocks MYC transformation activity (146). In 2002, Elizabeth M. 
Flinn et al., definitively define Myc box II as domain responsible for c-Myc interaction with GCN5 
or its associated protein, TRRAP (146). 
The basal transcription factor 1 (SP1), a critical zinc-finger GC binding protein, is clearly involved 
in N-Myc-mediated repression mechanism (147-150). The N-Myc and SP1 interaction was fully 
investigated (151) through both ex-vivo and in-vitro techniques, resulting in demonstrating the 
importance of Myc Box 2 as the domain responsible for the interaction with SP1. As already 
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mentioned, N-Myc-SP1 complex exerts repressive function via recruitments of chromatin modifiers 
such as histone deacetylases. In 2007, Marshall et al. demonstrated the role of N-Myc-SP1 complex 
in repression activity of the transglutaminase 2 (TG2) gene expression through recruitment of 
histone deacetylase 1 (HDAC1)(147). Importantly, ChIP assays have determined that MAX is not 
present at DNA level and is not necessary for HDAC1 recruitment. Hence, N-Myc-SP1 repressive 
activity can be established in absence of N-Myc “partner” and can be disrupted by the use of an 
HDAC1 inhibitor (trichostatin A) (148).  
In 2010 Marshall et al. have also demonstrated the N-Myc-SP1 mediated inhibition of CyclinG2 
gene transcription through the interaction with HDAC2. Accordingly, in 2012 Zhang et al. have 
revealed that both c-Myc and N-Myc can interact with paralogs of HDAC1 such as HDAC2 and 
HDAC3 (152).  
In-vitro analyses of the N-Myc regions required for its interaction with both SP1 and MIZ-1 show 
that N-Myc Myc Box 2 domain can directly interact with SP1, while the basic helix-loop-helix 
leucine-zipper (BR/HLH/LZ) domain is required for interaction with MIZ-1. The “ternary 
complex” can also drives the transcriptional repression of genes such as TRKA (tyrosine kinase 
receptor A), P75NTR (p75 neurotrophin receptor), and CKN1A(p21) in neuroblastoma by 
recruitment of HDAC1 on the respective promoters (151). 
Collectively, these findings highlight the complexity of N-Myc activity and suggest that many more 
nuclear components may be critical for N-Myc-mediated transcriptional activation/repression.  
The main goal of the present study is to shade light on new possible functional and physical 
interactions between N-Myc and the two protein factors strictly associated with histone methylation: 
WDR5 and LSD1.   
 
WDR5 METHYLTRANSFERASE 
 
After the discovery of the COMPASS methyltransferase complex (complex of proteins associated 
with Set1) in yeast, in mammals too more than six COMPASS-like complexes were revealed. 
Although in yeast Set1 is the sole catalytic subunit of COMPASS complex, in mammals the situation 
is more complicated because of 2 orthologs (Set1a and Set1b) and 2 paralogs (MLLs and Ash1) 
(Table.2).  
COMPASSes are multi subunits complexes with mono-, di- or tri-methylating activity on lysine 4 of 
histone H3 N-tail. Affinity pull-down experiments in mammals samples revealed the presence of 
WDR5 protein as one of the COMPASS subunits directly interacting with H3K4 (153, 154). 
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In this connection, recent studies have underlined the central role of Cps30 in yeast, and its 
mammals homolog WDR5, in the catalytic activity of COMPASS complexes for H3K4Me1-Me2 
recognition and tri- or di-methylation (155).  
 
 
 
 
 
 
 
 
 
     
 
 
 
Table.2: Yeast and mammalian COMPASS subunits and their functions (153).  
 
The physical interaction between WDR5 and the conserved “Win” motifs of all the SET1 family 
members has also already been fully been demonstrated. Moreover, peptides that mimic both “Win” 
motif and H3K4 can distrupt the interaction between WDR5 and its partners. The actual 
mechanism hypothesized is the mutually exclusive binding to mono or di-methylated lysine 4 of H3 
and the Win motif of Set1 proteins (155-157). 
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Figure 10: COMPASS and COMPASS-like complexes from yeast to human. COMPASS was identified in 
yeast as a complex of proteins associated with Set1 that can methylate H3 on Lys 4. Subsequently, six 
COMPASS-like complexes were identified in humans. All complexes share the core components Cps30 
(WDR5), Cps50 (RBBP5), Cps25 (DPY30), and Cps60 (ASH2). COMPASS in humans also has CXXC and 
WDR82, which are homologous to Cps40 and Cps35 in yeast and regulate H3K4 trimethylation by 
COMPASS in vivoThe MLL3/4 complexes also contain the H3K27 demethylase UTX. The MLL1–4 
COMPASS-like complexes function as coactivators of gene transcription in contrast to the canonical 
COMPASS complexes in yeast and humans. Set1s/MLLs are colored red, core components are colored green, 
and subunits with complex- specific functions are colored purple (157). 
 
To better understand the mutual binding of WDR5 with MLL or Set1, in-vitro competition assays 
have shown that only H3K4Me1-Me2 peptides can disrupt the interaction, whereas H3K4 and 
H3K4Me3 cannot (156, 157). WDR5 interaction with catalytic subunits, MLL or Set1, is an 
essential step not only for COMPASS complex assembly but also for its core-catalytic 
methyltransferase activity (Figure 10)(158).  
Although, most WDR5 related studies have been confined to its role in methyltransferase 
complexes, some recent data collected both in drosophila and in human cell lines, have revealed its 
possible role in structural nucleation of other protein complexes in which neither MLL or Set1 were 
detected (159).  
There are very few data about WDR5 implication in carcinogenesis events. Some recent studies have 
revealed an important pattern of WDR5 over-expression in many human prostate cancer samples; 
ex-vivo experiments carried out on LNcaP cell line have underlined the involvement of WDR5, 
cooperating with H3T11P, in globally alteration of the methylation status of several AR target genes 
resulting in a boost of proliferation rate (154).  
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DE-METHYLASES AND LSD1 
 
In general, histone methylation turn over is slower than of other histone markers, and until the 
discovery of enzymes capable to de-methylate this marker was believed to be “irreversible” (144). 
There are at least two main models that try to explain the turnover of methyl groups on histones. 
One suggests direct histone tail removal (Allis et al., 1980) or replacing with the methylated histone 
variant (160). However, this mechanism would not allow for dynamic regulation of histone 
methylation and the plasticity that may be essential for gene transcription regulation in some 
biological processes. The second hypothesis is based on the potential activity of de-methylase 
enzymes that remove methyl groups from lysine and arginine, which would make dynamic 
regulation possible (144). 
In 2004 was discovered the antagonizing activity of the human Peptidyl Arginine DeIminase 4 
(PADI4/PAD4) with respect to the methylation of arginine residues (161, 162). Thus far, no 
specific arginine de-methylases were discovered (144). These findings suggested that histone 
methylation can be “contrasted” by dynamical regulation and activity of deiminase enzymes (144). 
There are two main classes of histone demethylase: FAD dependent LSD de-methylases and JmjC 
which use  Fe2+ and α-	  ketoglutarate as co-factors (144). 
In 1973 Paik et colleagues first partially purified histone de-methylating catalytic activity and 
opened up the possibility of fully understanding the histone de-methylation pathway (163). In 2002 
Bannister et al. proposed the role of some amineoxidase enzymes in histone de-methylation via an 
oxidation reaction that removes methyl groups from lysine or arginine residues (164). In 2004 Shi et 
el. discovered a protein (encoded by KIAA0601 gene) that shares significant sequence homology 
with FAD-dependent amine oxidases and because of its ability to specific demethylate lysine 4 of 
histone H3 was named as LSD1 ( Lysine DeMethylase 1A) (163). 
Human lysine (K)-specific histone demethylase (LSD1) is a flavin-containing amino oxidase that 
specifically catalyzes the demethylation of mono- and di-methylated histone H3 lysine residues 
through a FAD-dependent oxidative reaction. Indeed, about 70% of the C-terminal region of LSD1 
displays significant sequence homology with FAD-dependent amine oxidases (163, 165). 
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protruding tower domain and a C-terminal amine oxidase (AO) domain
[22]. The SWIRM and AO domains interact to form a core structure that
binds FAD not covalently and serves as the enzymatic domain; the
tower domain provides a surface platform for interaction with partners
(Fig. 1B). Because of the strong structural andmechanistic similarities be-
tween LSD1 catalytic domain and conventional amine oxidases, mono-
amine oxidase (MAO) inhibitors as the tranylcypromine (TCP),
covalently bind FAD and inhibit LSD1 activity [23]. On the other hand,
pargyline, a propargylamine containing small molecule initially pro-
posed as LSD1 inhibitor, failed to appreciably inactivate LSD1 in subse-
quent studies [21,24,25]. A series of new tranylcypromine analogs
have been developed and biochemical and biological evaluation of
their inhibitory properties and efﬁcacy for human LSD1 and LSD2 has
been assayed [23–25]. Some of these compounds are effective LSD1 in-
hibitors, andmost importantly they exhibit in vivo efﬁcacy in tumors by
altering the chromatin state and synergistically cooperate with
antitumoral drugs [24,25].
The molecular mechanism underlying LSD1 transcriptional regula-
tion remains confuse, essentially because LSD1 associates with different
complexes and it can function as co-repressor or co-activator in a target-
speciﬁc manner. LSD1 has been found in different transcriptional
complexes involved in transcription repression such as CoREST and
NuRD (Fig. 1C) [13]. Consistent with its role in transcription repression,
LSD1 demethylates monomethyl and dimethyl histone H3 lysine 4
(H3K4me1 and H3K4me2), which are marks of active chromatin tran-
scription state.
LSD1 has also been found to have a role in transcriptional activation
as exempliﬁed by the nuclear hormone receptors induced transcription.
The interaction of LSD1 with androgen (AR) or estrogen (ER) nuclear
receptors seems to change its substrate speciﬁcity from H3K4me1/
me2 to H3K9me1/me2 [26–31];moreover, it has been recently reported
that, following hormone treatment, protein kinase C is recruited to AR
target promoters and phosphorylates H3 threonine 6 (H3T6). This mod-
iﬁcation switches LSD1 H3K4 demethylating activity from H3K4me2 to
H3K9me1 and H3K9me2 [27]. Also, ER mediated demethylation of
H3K9 by LSD1 has been hypothesized to be due to H3K9 demethylase
associated with LSD1 or to a reader of H3 methylation that changes
LSD1 speciﬁcity [31]. As demethylation reaction by LSD1 release H2O2,
it has been proposed that LSD1 recruitment by ER and Myc on their
respective targets, triggers DNA oxidation and recruitment of base exci-
sion repair enzymes that favors chromatin looping for transcriptional
activation–repression [28,32,33]. More recently, LSD1 was found to be
part of protein complexes responsible for transcription elongation: the
ELL complex containing the P-TEFb transcriptional elongation factor
and the MLL super-complex containing both transcriptional activators
and repressors [34,35].
It is evident that association of LSD1 with speciﬁc partners deter-
mines its substrate speciﬁcity. Moreover, concomitant histone modiﬁ-
cations such as deacetylation or phosphorylation may inﬂuence LSD1
activity as H3K9 acetylation and/or H3S10 phosphorylation negatively
affect LSD1 H3K4 demethylase activity [11,21,24,26].
3. Non-histone LSD1 substrates
It has been found that LSD1 demethylates also non-histone proteins.
LSD1 speciﬁcally demethylates p53 dimethylated K370 residue, signiﬁ-
cantly altering its function [36,37], indeed, dimethylated but not mono-
methylated p53 can interact with its coactivator 53BP1. These studies
point to an active involvement of LSD1 in the DNA damage response
pathway, via direct modulation of p53 activity, and suggest that LSD1
may inhibit apoptosis. LSD1 also inhibits DNA damage-induced cell
death in the absence of p53 throughmodulation of the E2F protein stabil-
ity [38,39]. Demethylation of E2F1 in lysine185 inhibits other E2Fmodiﬁ-
cations that drive E2F degradation thus, favoring E2F accumulation
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targets.
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        Figure 11: Schematic representation of the LSD1 protein domains organization (166). 
                                             
As schematized in figure 11, LSD1 protein is composed by three domain: SWIRM 
(Swi3p/Rsc8p/Moira), TOWER and the Amino Oxidase domains, AOs. The N-terminal SWIRM 
domain interact with AO domains to form the catalytic site of non covalent FAD binding (166). 
LSD1 protein has been isolated as a stable component in a number of corepressor complexes(Figure 
12) including CoREST, CtBP, and histone deacetylase I and II (HDAC) (167, 168).  
 
 
 
 
 
 
 
 
Figure 12: LSD1 as part of the Co-REST complexes contributes to repression of transcription by removing 
H3K4 methylation (165). 
 
Biochemical characterization of the demethylation activity of LSD1 has shown that FAD is required 
during the removal of a methyl group in a reaction that produced H2O2 and formaldehyde as 
products (Figure 13) (163). Recombinant LSD1 alone can demethylates H3K4 di-methylated in 
histone substrates that have been stripped of associated DNA. In vitro studies have revealed that Co-
REST, part of LSD1/Co-REST complexes, is required for LSD1 ability to be able to demethylate 
nucleosomal substrates. Indeed, reconstitution experiments using purified recombinant factors have 
demonstrated that an LSD1–Co-REST complex is sufficient for demethylation reaction (163, 168).  
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Figure 13: The LSD1 reaction mechanism detailing the removal of a mono- methyl group. LSD1 is proposed 
to mediate demethylation of mono- and di-methylated lysine residues through an amine oxidation reaction 
using FAD as a cofactor. Loss of the methyl group from mono-methyl lysine occurs through an imine 
intermediate (1), which is hydrolysed to form formaldehyde by a non-enzymatic process (165). 
 
The association of LSD1 with Co-REST repression complex unquestionably suggest its role in 
negative transcription regulation. In 2001 Ballas et al. using mouse inducible cell lines, have 
reported that REST gain of function represses neural-specific gene expression and blocks the 
terminal differentiation process (169). 
LSD1 being a component of several repressive complexes including deacetylase activity and 
recognizing an extended portion of the histone H3 tail, it has been hypothesized that specific 
recognition of lysine 4 of histone H3 might be guided by deacetylation events at other residues on 
the same histone tail. In support of this hypothesis, less efficiently activity of the LSD1–Co-REST 
complex on hyperacetylated nucleosomes has been reported (170). Further, LSD1 mediated 
demethylation of H3K4 peptides is completely abolished when the latter also contain acetyl groups 
on K9, K14 and K18. Furthermore, in-vitro experiments using purified factors show that 
demethylation of histone N-tails is favoured by the presence of HDAC1 in the LSD1–Co-REST 
complex (171).  
Therefore, H3K4 demethylation and histone deacetylation by LSD1-containing complexes seems to 
be tightly coupled with both activities, contributing to the overall repressive functions of these 
complexes. As mentioned above, the heterogeneous methylation pattern in different N-tail residues 
may determine a different pattern of regulatory proteins that can both determine active transcription 
or repression. 
In addition to its role as a repressor, LSD1, has been reported to form a complex with the androgen 
receptor (AR) producing a demethylase activity on H3K9, allowing it to function as a transcriptional 
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activator. During hormone-induced transcriptional activation, LSD1 is partially required for H3K9 
demethylation and AR transactivation. The specific mechanism by which the AR alters LSD1 
specificity remains unknown (172). 
In 2010 Amente et al. have reported the association of LSD1 with c-Myc in Rat-1 cell line and also 
demonstrated the functional activity of H3K4Me2 de-methylation in c-Myc-mediated gene 
activation (173). 
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NEUROBLASTOMA AND WDR5 
 
Chromatin modifications, including histone methylation, have a crucial role in transcription mis-
regulation of many cancer-related genes. Mono-, di-, and tri-methylation of H3K4 mark the 
promoter and enhancer regions of active genes (174, 175). These three methylation variants are 
deposited by the SET1/MLL histone methyltransferase (HMTase) complex (COMPASS), which, at 
its core, is composed of either KMT2A/MLL1, KMT2B/MLL2, KMT2C/ MLL3, KMT2D/MLL4, 
SETD1A, or SETD1B associated with WRAD module (WDR5, RBBP5, ASH2L, and DPY30) and 
other variable partners (157, 176). Interestingly, WDR5 subunit directly binds both unmodified 
and methylated H3K4 in-vitro and is required for the tri-methylation of this residue by the 
SET1/MLL complex (154, 156). 
To this day, there are not studies focusing on the role of WDR5 in neuroblastoma cancer 
development and/or progression.  
In collaboration with Prof. Tao Liu (CCIA-Sydney), protein expression analysis from 69 
neuroblastoma tumor tissues samples (data not shown) have revealed that high levels of WDR5 
protein are significantly associated with reduced overall survival.  
Accordingly, meta-analyses of the publically available (http://r2.amc.nl) Versteeg (177) microarray 
gene expression datasets showed that high levels of WDR5 mRNA expression in neuroblastoma 
tissues are directly correlated with N-Myc mRNA expression (Versteeg dataset: R = 0.269, 95% CI = 
0.06 to 0.45; P = .012)(Figure 14, upper graph) and poor overall survival rates (Figure 14, lower 
graph) (Versteeg dataset: HR = 4.17, 95% CI = 1.27 to 5.65; P = .0096) 
Additionally, high levels of WDR5 expression in 72 N-Myc-amplified (data not shown) 
neuroblastoma tissues were positively associated with poor overall patient survival in the large Kocak 
dataset. 
Based on these finding it has been decided to investigate the role of N-Myc in direct regulation of 
WDR5 expression and also to better define the mechanisms by which N-Myc and WDR5 can 
directly or indirectly interact to alter the expected neuroblastoma prognosis. Specifically, qRT-PCR 
expression analyses and immunoblot assays were carried out on N-Myc amplified Neuroblastoma 
cell lines SK-N-BE (2C) and CHP-134 to assess the role of both N-Myc and WDR5 in the 
alteration of WDR5, CCNE1 and MDM2 gene signature. Moreover, Ch-IP experiments were 
performed in order to assess the role of both N-Myc and WDR5 factors in transcription factors 
occupancy and H3K4Me3 signature.  
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Figure 14: Prognostic significance of WDR5 expression in neuroblastoma. Upper graph, two-sided Pearson’s 
correlation was employed to analyze correlation between WDR5 and N-Myc mRNA expression in 88 human 
neuroblastoma samples in the publically available microarray gene expression Versteeg dataset downloaded 
from R2 microarray analysis and visualization platform (http://r2.amc.nl). Lower graph) Kaplan–Meier curves 
showed the probability of overall survival of patients according to the levels of WDR5 mRNA expression in 
the 88 neuroblastoma patients in the Versteeg datasets.  
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N-MYC POSITIVELY REGULATES WDR5 EXPRESSION BY DIRECLY BINDING E-BOXES 
 
N-Myc activates gene transcription by binding to E-Box sequences at target gene promoters (33).  
In silico analysis of WDR5 gene promoter have revealed two non-canonical (CACGCG) (-13 to -18 
bp) and two canonical (CACGTG) (+85 to +90 bp) E-box sequences (Figure 15, left). Based on 
this, it was decided to examinee whether N-Myc modulates WDR5 expression. To address this point 
qRT-PCR analysis and immunoblot assays were performed in the N-Myc-amplified human 
neuroblastoma cell lines, SK-N-BE(2)-C and CHP134. Specifically, siRNA silencing of N-Myc 
(20pmol 72h) was performed in both cell lines to seek differences in WDR5 RNA and protein level. 
All the qRT-PCR experiments were carried out in triplicate and the reference genes used for 2^(-
DDCT) normalization are GUSB (GlUcuronidaSeBeta) and B2M (Beta 2 Microglobulin).  
As shown in Figure 15 A and B, qRT-PCR analysis carried out on SK-N-BE (2)-C and CHP-134 
transiently transfected with both N-Myc siRNA-1 or N-Myc siRNA-2 significantly reduce WDR5 
mRNA level. Accordingly, western blot assays presented in figure 15 A and B confirm that N-Myc 
silencing lead to WDR5 repression also at protein level. As negative samples both cell lines were 
transfected with control siRNA. 
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Figure 15:	  Effect of N-Myc on WDR5 expression. SK-N-BE(2)-C (A)and CHP134(B) cells were transfected 
with control siRNA, N-Myc siRNA-1 or N-Myc siRNA-2 for 72 hours, followed by RT-PCR (left)  and 
immunoblot (right) analyses of N-Myc and WDR5 expression. White bars indicate control siRNA sample, 
bright grey and dark grey are respectively N-Myc siRNA-1 and 2. Statistical analysis was performed by using 
two-way ANOVA. Error bars represented SD. *, ** and *** indicated P < .05, .01 and .001 respectively.  
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To fully corroborate the hypothesis that N-Myc directly regulates WDR5 expression by binding to 
E-box elements, Chromatin ImmunoPrecipitation (Ch-IP) assays were performed in SK-N-BE(2)-C 
cells with a control (normal IgG) or monoclonal anti-N-Myc antibody. All the experiments were 
carried out in triplicate and the analysis of immunoprecipitated DNA was performed with Real time 
PCR.  
As shown in Figure 16, the anti-N-Myc antibody efficiently immunoprecipitated the WDR5 gene 
promoter regions containing both canonical and non-canonical E-boxes (Amplicon B). 
qRT-PCR, Western-blot and ChIP data strongly indicate that N-Myc up regulates WDR5 gene 
expression in neuroblastoma cell lines with N-Myc amplification by directly binding to the WDR5 
gene promoter.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Schematic representation (left) of the WDR5 gene promoter. TSS represented transcription start 
site. ChIP assays (right) were performed with a control or anti-N-Myc antibody (Ab), followed by Real-time 
PCR with primers targeting the negative control region (Amplicon A, white bar) or the WDR5 gene 
promoter containing the E-box (Amplicons B, grey bar and C black bar) in SK-N-BE(2)-C cells. Fold 
enrichment of the WDR5 gene promoter was calculated as the difference in cycle thresholds obtained with 
the anti-N-Myc Ab and with the control Ab. Error bars represented SD.  
 
 
 
 
 
 
 
	   42	  
WDR5 POSITIVELY REGULATE MDM2 EXPRESSION 
 
As WDR5 exerts biological function by modulating gene transcription, differential gene expression 
studies were performed, in collaboration with Prof. Tao Liu, with Affymetrix microarray in SK-N-
BE(2)-C cells, 40 hours after transfection with control or WDR5 siRNAs (data not shown). The 
analyses have showed that well-known N-Myc target genes CyCliN E1 (CCNE1) and MDM2 (33, 
178, 179), were among the genes significantly down modulated by WDR5 siRNAs. QRT-PCR and 
immunoblot have validated the microarray data and confirmed that both WDR5 siRNA 1 and 2 
decreased MDM2 mRNA and protein expression in neuroblastoma cell lines (Figure 17, A, B and 
C).    
Specifically, siRNA silencing of WDR5 (20pmol 72h) was performed in both cell lines to seek 
differences in MDM2 RNA and protein level. All the qRT-PCR experiments were carried out in 
triplicate and the reference genes used for 2^(-DDCT) normalization are GUSB 
(GlUcuronidaSeBeta) and B2M (Beta 2 Microglobulin) 
As shown in figure 17 panel A and B, both WDR5 siRNA-1 and siRNA-2 significantly reduce gene 
expression of WDR5, CCNE1 and MDM2 in SK-N-BE (2)-C and CHP-134 neuroblastoma cell 
lines. Western blot analysis (Figure 17 panel C) also demonstrate reduced MDM2 protein levels 
after WDR5 knocking down with both siRNA-1 and si-RNA-2. As negative samples both cell lines 
were transfected with control siRNA. 
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Figure 17: Effect of WDR5 on gene transcription. SK-N-BE(2)-C and CHP134 cells were transfected with 
control siRNA, WDR5 siRNA-1 or WDR5 siRNA-2. WDR5, CCNE1 and MDM2 mRNA (A and B) and 
protein expression (C) was analyzed by RT-PCR and immunoblot. White bars indicate control siRNA 
sample, bright grey and dark grey are respectively WDR5 siRNA-1 and 2. Statistical analysis was performed 
by using two-way ANOVA. Error bars represented SD. *, ** and *** indicated P < .05, .01 and .001 
respectively.  
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WDR5 IS ESSENTIAL IN N-MYC-WDR5 COMPLEX IN BINDING MDM2 PROMOTER 
 
Because bioinformatics analysis located a canonical E-box at the MDM2 gene promoter (Figure 18, 
A), we performed dual cross-linking ChIP assays in SK-N-BE(2)-C cells with control, anti-N-Myc 
and anti-WDR5 antibodies, followed by Real time PCR with specific primers targeting a negative 
control region or the MDM2 gene promoter. The results showed that the anti-N-Myc and the anti-
WDR5 antibodies efficiently immunoprecipitated the MDM2 gene promoter region containing the 
E-box, compared with the negative control region (mean fold of control antibody ± SD: N-Myc 
antibody, 7.48 ± 3.91; WDR5 antibody, 31.47 ± 4.28; P < .01, two-way ANOVA) (Figure 18, B).  
To understand whether WDR5 is essential for both histone H3K4 trimethylation and N-Myc 
binding to the MDM2 gene promoter, we transfected SK-N-BE(2)-C cells with control or WDR5 
siRNAs, followed by ChIP assays with a control, anti-N-Myc or anti-tri-methylated H3K4 
(H3K4me3) antibody. QPCR analyses have showed that knocking-down WDR5 expression 
significantly reduced the N-Myc occupancy (mean fold of N-Myc/control antibody ± SD: control 
siRNA-1, 5.37 ± 2.17; WDR5 siRNA-1, 2.92 ± 1.04; WDR5 siRNA-2, 3.24 ± 1.09) and 
trimethylation of histone H3 lysine 4 (mean fold of H3K4me3/control antibody ± SD: control 
siRNA-1, 1197 ± 971.6; WDR5 siRNA-1, 413.7 ± 236.1; WDR5 siRNA-2, 279.5 ± 387.3) (P < 
.001, two-way ANOVA) at the MDM2 gene promoter in SK-N-BE(2)-C cells (Figure 18, C and 
D).  
Collectively, these data suggest that both WDR5 binding and activity are probably required for N-
Myc protein binding and histone H3K4 trimethylation at the MDM2 gene promoter.  
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Fig.18: A) Schematic representation of the MDM2 gene promoter containing the N-Myc binding E-box. B) 
Dual cross-linking ChIP assays were performed in SK-N-BE(2)-C cells with control, anti-N-Myc and anti-
WDR5 antibodies (Abs), followed by qPCR with primers targeting the negative control region (Amplicon A) 
and the N-Myc binding site (Amplicon B) of the MDM2 gene promoter. C-D) SK-N-BE(2)-C cells were 
transfected with control siRNA, WDR5 siRNA-1 or WDR5 siRNA-2 for 48 hours, followed by ChIP assays 
with a control IgG, anti-N-Myc (C) or anti-tri-methyl H3K4 (H3K4me3) (D) Ab, and qPCR with primers 
targeting the negative control region or the E-box of the MDM2 gene promoter. Fold enrichment of the 
MDM2 promoter region was calculated as the difference in cycle thresholds obtained with the specific Ab and 
with the control IgG. Error bars represented SD. *, ** and *** indicated P < .05, .01 and .001 respectively.  
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N-MYC AND WDR5 FORM A PROTEIN COMPLEX 
 
As histone H3K4 trimethylation is essential for Myc binding to target gene promoters and WDR5 
induces histone H3K4 trimethylation (70, 180), it has been examined whether N-Myc and WDR5 
formed a protein complex. To address this point Co-immunoprecipitation assays were performed on 
SK-N-BE-(2C) neuroblastoma cell line. Specifically, 1mg of crude nuclear protein extract from SK-
N-BE-(2)-C was immunoprecipitated with specific antibodies against N-Myc and WDR5. Normal 
IgG were used as negative control. Recombinant-Protein A sepharose  beads were used for protein 
complexes isolation. After elution, immunoprecipitated samples were analysed by western blot. As 
shown in figure 19, anti-N-Myc antibody efficiently co-immunoprecipitated WDR5 protein, and 
accordingly, anti-WDR5 antibody efficiently co-immunoprecipitated N-Myc protein (Figure 19), 
demonstrating that the two proteins form a protein complex.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Co-IP assay, 1mg of crude nuclear protein extract from SN-K-BE(2) neuroblastoma cells was 
immunoprecipitated (IP) overnight with 2 µg of control IgG, anti-N-Myc or anti-WDR5 antibody (Ab). 
Immunoprecipitated protein was immunoblotted with anti-WDR5 or anti-N-Myc Ab. 
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Next, Tet-21/N neuroblastoma cells were treated with vehicle control or tetracycline to induce or 
not to induce exogenous N-Myc expression, respectively (26). The cells were then co-transfected 
with control or WDR5 siRNAs, together with a pGL3 luciferase report construct expressing wild 
type or E-box mutant MDM2 gene promoter (178).  
Luciferase assays showed that N-Myc induction resulted in a significant increase in luciferase activity 
in cells transfected with the wild type, but not the E-box mutant, MDM2 promoter construct. In 
addition, WDR5 siRNAs considerably reduced N-Myc-mediated wild-type MDM2 promoter 
activity [mean fold of N-Myc (+)/N-Myc (-) ± SD: control siRNA-1, 3.51 ± 0.40; WDR5 siRNA-1, 
2.04 ± 0.35; WDR5 siRNA-2, 2.15 ± 0.76; P < .001, two-way ANOVA) (Figure 20). Taken 
together, the data suggest that WDR5 forms a protein complex with N-Myc at the N-Myc target 
MDM2 gene promoter, leading to histone H3K4 trimethylation and N-Myc target gene 
transcription.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Tet-21/N neuroblastoma cells were cultured with tetracycline to not induce, or without 
tetracycline to induce, N-Myc expression, respectively. The cells were co-transcfected with a luciferase 
reporter construct expressing wild type or E-box mutant MDM2 gene promoter, together with control 
siRNA, WDR5 siRNA-1 or WDR5 siRNA-2. Luciferase assays were performed, and relative luciferase 
activity of the wild type and the mutant MDM2 promoter constructs under the N-Myc (+) condition was 
normalized by the luciferase activity of the same reporter construct under the N-Myc (-) condition. Error bars 
represented SD. *, ** and *** indicated P < .05, .01 and .001 respectively. 
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N-MYC AND LSD1 
 
Childhood neuroblastoma is the most common solid tumour of infancy, and is highly refractory to 
therapy. One of the most powerful prognostic indicators for this disease is the N-Myc gene 
amplification, which occurs in approximately 25% of neuroblastomas (181). The N-Myc 
oncoprotein is a member of the well-known family of transcription factors MYC, belong to a subset 
of the larger class of proteins containing Basic-Region/Helix–Loop–Helix/Leucin-Zipper 
(BR/HLH/LZ) motif. Trough BR/HLH/LZ domain N-Myc interact with MAX (Myc Associated 
X-factor), and as heterodimers they act as transcription regulator. As mentioned above, N-Myc can 
be part of different chromatin regulating complexes composed by several components including 
histone modifiers (45). There is extensively documented the role of N-Myc protein in negative 
transcription regulation of many cancer related genes involved in several important biological 
processes like cell cycle control and migration/motility behaviours (37).  
In 2013 Corvetta et al. have carried out a deep investigation into mechanism of N-Myc negative 
regulation against the neuroblastoma oncosuppresor Clusterin (CLU) through direct binding to 
non-consensus E-box sequences. They also demonstrated the physical and functional interaction 
between N-Myc and EZH2, methyltransferase part of the Polycomb Repression complex 2 (111). 
There has also been extensive discussion of the role and actual mechanism of both c-Myc and N-
Myc in negative regulation of CKN1A(p21) gene signature. 
It was previously reported that LSD1 expression inversely correlates with differentiation status of 
primary neuroblastic tumors. Consistently, in vitro differentiation assays performed on 
neuroblastoma cells have clearly indicated a down-regulation of LSD1, and accordingly inhibition or 
knockdown of LSD1 resulted in differentiation events and reduced cells viability (182). In 2010 
Amente et al. have largely discussed the role of c-Myc in LSD1 recruitment on MYC target genes 
during early transcription events (173).  
The present study explored the functional and physical interaction between N-Myc and LSD1 in 
modify transcription profiles of two neuroblastoma critical genes, CKN1A(p21) and CLU. 
Specifically, ex-vivo and in-vitro techniques have suggested that Myc Box III of N-Myc is involved in 
N-Myc-LSD1 complex. Moreover, qRT-PCR analysis have underlined the critical role of both 
factors in negative modify CKN1A(p21) and CLU gene signature. Pharmacological treatment was 
also performed that was intended to inhibit both N-Myc and LSD1 activity to investigate changes in 
neuroblastoma in cell viability and apoptosis.  
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LSD1 INTERACTS WITH N-MYC 
 
LSD1 can form different transcription complexes possessing either repression or activation 
capacities. As already mentioned, c-MYC interacts with LSD1 and because c-MYC and N-Myc 
proteins are extensively conserved both structurally and functionally, it has been decided to 
determine whether LSD1 and N-Myc can associate with one another in a neuroblastoma cellular 
context. In figure 21 panel C are depicted different fragments of N-Myc used for both ex-vivo and 
in-vitro pull down assays.  Co-immunoprecipitation assays were performed in the human N-Myc 
amplified SK-N-BE- (2)-C neuroblastoma cell line. Specifically, 500ug of crude nuclear extracts 
were immunoprecipitated with an monoclonal antibody against N-Myc and normal IgG as negative 
control. Immuno-complexes were purified using recombinant protein-G, eluted and then separated 
by SDS-PAGE. Immunoblot analysis have revealed that only N-Myc-IPs extracts can efficiently 
pull-down endogenous LSD1, demonstrating that high levels of N-Myc can form a complex with 
LSD1 (Figure 20A).  
To better characterize the N-Myc domain involved in N-Myc-LSD1 complex formation pull-down 
assays were carried out, both ex-vivo and in-vitro, using mutant recombinant N-Myc proteins.  
Specifically, HEK-293T cells were co-transfected with expression vectors encoding human full-
length LSD1 together with a series of N-Myc expressing vectors containing different cDNA 
deletions, d1(1-300aa), d2(1-134aa),and d3(20-90aa). Crude cell extracts were immunoprecipitated 
with a N-Myc specific antibody, purified and separated by SDS-PAGE. Western blots analyses, as 
shown in Figure 21 (panel B), have revealed that LSD1 co-immunoprecipitation was not observed 
with extracts from cells co-transfected with N-Myc mutant d1, while d2 and d3 deletion constructs 
retain the ability to bind LSD1. These results suggest that MYC-Box III is involved in interaction 
between N-Myc and LSD1 (Figure 21, A and B). To confirm in-vitro which N-Myc domain can 
interact with LSD1, a pull down assay was set up using 7 GST-N-Myc overlapping fragments (from 
N1 to N4B, Figure 21, panel C) and recombinant full length LSD1_3xFlag protein. The seven 
segments were expressed in E.Coli (BL-21 strain) and then GST recombinant proteins were purified 
on Gluthatione agarose beads (Sigma-Aldrich). 40µg of crude nuclear protein extracts from HEK-
293T cells transiently over expressing exogenous LSD1_3xFlag were incubated with Glutathione 
agarose beads coated with all the seven GST-N-Myc segments. Protein complexes purified were 
eluted and the interaction between recombinant GST-N-Myc fragments and exogenous 
LSD1_3xFlag was determined by western blot analysis using specific antibody against 3xFlag and 
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GST (Figure 21, panel D). Consistently with Co-immunoprecipitation assay result (Figure 21, panel 
A), only one distinct region of N-Myc, containing the MB III domain, can interact with LSD1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: N-Myc physically interacts with LSD1. A, co-immunoprecipitation assay between endogenous 
LSD1 and N-Myc in SK-N-BE (2C) cells. Nuclear lysates from SK-N-BE (2C) cells were immune-
precipitated with a N-Myc antibody and a generic IgG antibody  was used as negative control. Western blot 
analysis was performed on immuno-purified extracts with N-Myc and LSD1 antibodies as indicated.  
B, N-Myc-LSD1 interaction. 293T were cells co-transfected with an LSD1 expression vector together with 
different N-Myc deletion expression vectors indicated in panel C. Extract from transfected cells were 
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Immuno-precipitated with a N-Myc antibody and analyzed by western blotting. C, schematic representation 
of N-Myc deletion mutants d1, d2 and d3 used in the CoIP assay and of GST-N-Myc constructs used in 
GST-pull down described in panel D. D, immobilized GST- N-Myc polypeptides were incubated with equal 
amounts of extract prepared from HEK 293T cells transfected with the recombinant vector LSD1-3xFLAG 
protein, separated by SDS-PAGE, and probed with an anti-LSD1 antibody. 
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LSD1 INHIBITION RELEASES N-MYC-MEDIATED REPRESSION OF CDKN1A  
 
To examine the putative LSD1 role in N-Myc mediated transcription it has been decided to 
investigate the relative levels of CKN1A(p21) gene expression in relation to N-Myc and LSD1 
expression in the conditional (TET-OFF system) neuroblastoma N-Myc expressing SHEP Tet-21/N 
cells in the presence or absence of functional LSD1. The relative RNA expression levels of N-Myc, 
LSD1 and CDKN1A(p21) were determined by qRT-PCR in tetracycline treated (High N-Myc) and 
untreated cells (Low N-Myc), in the presence or absence of functional LSD1 obtained through 
pharmacological functional inhibition by tranylcypromine (TCP). Furthermore, the expression of 
above cited genes has also been analysed after LSD1 expression ablation using its sequence-specific 
sh-RNA (sh-LSD1) using Sh-RNA non silencing as control. Western blot analysis of Sh-RNA 
efficiency to knock-down LSD1 protein levels is presented in figure 22 panel D. The experiments 
were performed in triplicate and statistical significance was calculated by two-way ANOVA 
algorithm.  
Congruously with previous studies, Tet-21/N cells displayed CKN1A(p21) de-expression in 
function of N-Myc levels while LSD1 expression is not affected by N-Myc variations(Figure 22, A). 
Interestingly, we found that 12h of TCP treatment (1mM) as well as specific LSD1 silencing by sh-
RNA de-represses CKN1A(p21) expression also in presence of N-Myc over-expression. These 
findings are consistent with a functional role of LSD1 in N-Myc-mediated repression of 
CKN1A(p21) (Figure 22,B).  
To further corroborate these results it has been used a different approach to modulate N-Myc 
expression. Tet-21/N cells were treated for 7 days with tetracycline to lowering N-Myc levels (Figure 
22,C, black bar), then after washing out of tetracycline, cell samples were collected at 12 hrs in the 
presence or absence of TCP (Figure 22,C, respectively grey and green bars). As shown in Figure 22 
panel C, mRNA N-Myc levels were strongly induced after 12h of tetracycline removal. Conversely, 
LSD1 expression was largely unaffected. Re-activation of N-Myc (monitored 12 hrs after 
tetracycline removal) coincided with CKN1A(p21) repression, and this repression was counteracted 
by TCP treatments (Figure 22 C, green bar). Collectively, these results highlight the crucial role of 
LSD1 in N-Myc-mediated repression o CKN1A(p21) and demonstrate that LSD1 inhibition is 
sufficent to de-repress CKN1A(p21) expression in presence of high levels of N-Myc.  
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Figure 22: Relative fold expression levels of N-Myc, LSD1 and CKN1A(p21) were determined by qRT-PCR 
analysis with the indicated targets and samples by using GUSB as reference target and N-Myc HIGH (White 
bar) as reference sample for panel A and B and N-Myc LOW (Black bar) for panel C. Panel D, western blot 
analysis of transiently (48h) transduction of TET-21/N with ShRNA non silencing and LSD1. Statistical 
analysis was performed by using two-way ANOVA Error bars represented SD. *, ** and *** indicated P < .05, 
.01 and .001 respectively. 
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N-MYC AND LSD1 CO-LOCALIZE AT CDKN1A(P21) PROMOTER 
 
Expression analysis carried out on TET-21/N cells (Figure 23) clearly revealed the significant role of 
both N-Myc and LSD1 factors in CDKN1A(p21) negative gene regulation. 
To determine whether LSD1 directly binds regulatory elements of CKN1A(p21) gene, we 
performed ChIP assays on TET-21/N cells to monitor the relative binding of N-Myc and LSD1 in a 
condition of low N-Myc ( 1 week of tetracycline treatment), high N-Myc ( no tetracycline 
treatment), in the presence or absence of functional LSD1 (TCP treatment) and by sh-RNA-
mediated silencing of LSD1 expression. Immunoprecipitated samples were analysed by qPCR using 
specific primers for Transcriptional Start Site (TSS) region in the CDKN1A(p21) promoter and the 
upstream region (-3,3kb) was used as negative control. Data from three independent Chromatin-IP 
assays were used to make % of input graphs presented in Figure 23. Five different experimental 
conditions were designed to conditionally alter both N-Myc and LSD1 expression level and/or 
activity: N-Myc low (white bar), N-Myc high (black bar), Short hairpin non silencing-control (white 
bar with rhombi), TranylCyPromine TCP (grey bar) and Short hairpin LSD1 (bar with slanting 
lines). Specifically, N-Myc and LSD1 protein level were reduced by using respectively tetracycline 
treatment (one week 1µg/ml) and Short hairpin RNA against LSD1(48h), whereas LSD1 activity 
was reduced using TCP (Monoamine oxidase inhibitor) treatment for 12 hours at 1mM.  
As shown in Figure 23 (upper side) both N-Myc and LSD1 binds TSS region of CDKN1A(p21) 
gene promoter in TET-21/N cells with high level of N-Myc. Both TCP treatment and Short hairpin 
LSD1 silencing didn’t affect N-Myc binding, while a decrease of LSD1 occupancy is registered in 
case of low N-Myc condition. These data strongly suggest the role of N-Myc in LSD1 recruitment 
at TSS level of CDKN1A(p21) promoter. 
To fully corroborate the hypothesis by which N-Myc-LSD1 complex can negatively affect 
transcription of CKN1A(p21) gene, were also performed Chromatin-IP assays for four different 
Histone modification: H3 pan acetylated, H3K4Me2, H3K27Me3 and H3K9Me2.  
As shown in Figure 23 (middle part, left side) there is a strong repression of H3 acetylation,  positive 
transcription histone marker, in samples with high level of N-Myc. Coherently with expression data 
carried out in high N-Myc condition, both LSD1 silencing (Sh-LSD1) and inhibition (TCP) 
determine a huge increase of H3 Acetylation at TSS level of CKN1A(p21) promoter. 
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Figure 23: LSD1 and N-Myc bind and repress CKN1A(p21). Chromatin immunoprecipitation assays. N-
Myc, LSD1, antibodies were used in IPs. Immunoprecipitated samples were analyzed by qPCR using specific 
primers for CDKN1A promoter Transcriptional Start Site (TSS) and two upstream regions (-3.3 and - 2,2 
Kb). N-Myc-low (white bars), N-Myc-high (black bars), N-Myc-high TCP treated (grey bars), N-Myc-high 
shNS (dotted bars) N-Myc-high sh-LSD1 (diagonal stripes bars). LSD1 silencing in Tet-21/N cells 
transduced with shLSD1 and with sh-control was assayed by western blot shown infigure 22. Histone 
modifications at CKN1A(p21) promoter. H3Ac, H3K27me3, H3K4me2 and H3K9Me2 antibodies were 
used in IPs. Data from three independent ChIP assays and presented as % of input along with standard 
deviations, n=3. 
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As negative transcription histone marker was analysed tri-methylated Lysine 27 of Histone H3.  
Data presented in Figure 23 (lower side) show an almost 3 fold increase of H3K27Me3 histone 
marker level in case of N-Myc repression, whereas both LSD1 silencing and inhibition cause a 
decrease of this negative histone marker. 
Chromatin-IP assays were also performed on di-methylated Lysine 4 and 9 of histone H3 (Figure 
23, middle part right side and bottom part left side). H3K4Me2 and H3K9Me2 are also specific 
substrates of LSD1 de-methylation activity. Consistently with the important repressive role of N-
Myc in CKN1A(p21) transcription, high N-Myc level determine an almost 3 fold decrease of 
H3K4Me2 signal, whereas H3K9Me2 it seems to be not affected. Interestingly and coherently with 
data already presented by Lim S. et collegues (183), both inhibition and repression of LSD1 did not 
seems to affect H3K4Me2 signature at TSS level of CDKN1A(p21) promoter. H3K9Me2 
modification have also shown no important changes in all the experimental conditions used.    
Collectively, our findings suggest that both N-Myc and LSD1 bind to and repress CDKN1A(p21) 
promoter, and lowering N-Myc levels as well as LSD1-knockdown by shRNA decrease LSD1 
recruitment resulting in re-activation of CDKN1A(p21) expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   57	  
 
LSD1 AND N-MYC COOPERATIVELY REPRESS CLUSTERIN EXPRESSION 
 
It has been recently shown that N-Myc interacts with EZH2, a component of the Polycomb 
repressor complex PCR2 and that the N-Myc/EZH2 complex represses the tumor suppressor gene 
Clusterin CLU (111). Because LSD1 can form complexes with both N-Myc and EZH2 we 
hypothesize that LSD1 could contribute to CLU gene expression. 
To prove the function of LSD1 in CLU expression we treated Tet-21/N cells with TCP or knocked 
down LSD1 expression using its sequence-specific siRNA. Consistent with a repressive function of 
N-Myc (111), CLU expression is increased in Tet-21/N- cells treated with Tetracycline to lowered 
N-Myc expression. Thus, CLU expression inversely correlates with N-Myc relative expression levels. 
Interestingly, TCP treatment and LSD1 silencing by shRNA de-repress CLU expression even in the 
presence of N-Myc over-expression (Figure 24). These findings are consistent with a functional role 
of LSD1 in N-Myc-mediated repression of CLU.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: LSD1 and N-Myc cooperatively repress CLU expression. CLU gene expression was analyzed by 
qRT- PCR, using samples prepared from N-Myc-low cells and N-Myc-high cells untreated and treated with 
TCP or siLSD1 as indicated. Statistical analysis was performed by using two-way ANOVA Error bars 
represented SD. *, ** and *** indicated P < .05, .01 and .001 respectively. 
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To further determine whether LSD1 directly controls CLU expression we conducted ChIP assays in 
high or low expressing N-Myc Tet-21/N cells. Both N-Myc and LSD1 are recruited at the 
chromatin regulatory region of CLU, and accordingly with previous study, N-Myc binding to CLU 
promoter is a function of N-Myc abundance and LSD1 inhibition or protein ablation by shRNA 
does not reduce binding (Figure 25). It has also been revealed that LSD1 binds to CLU chromatin 
promoter and this binding increases in function to N-Myc abundance. ShRNA-mediated LSD1-
knockdown decreases the amount of LSD1 recruitment at the gene promoter while TCP treatment 
does not have any effect. Next, ChIP analysis have been carried out to determine modified histones 
at the CLU promoter. Like in low-expressing N-Myc, shRNA-mediated knockdown of LSD1 
enhanced H3-acetylation and it attenuated H3K4me27 (Fig 25), consistent with the induction of 
CLU expression in these cells. As already determined for N-Myc-LSD1 protein complex activity on 
CDKN1A(p21) Ch-IPs, H3K4Me2 and H3K9Me2 seems not to be affected by LSD1 negative 
silencing or repression.  
Collectively, these findings suggest that both N-Myc and LSD1 bind to CLU promoter chromatin, 
and demonstrate that CLU expression is repressed by N-Myc/LSD1 levels and that LSD1 inhibition 
rescues N-Myc-dependent repression. 
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Fig.25: N-Myc and LSD1 binding to CLU chromatin. Cell treatments are indicated at the bottom of the 
figure and described in the legend of Figure 24.  qPCR was performed with primers for CLU TSS, -1kb and 
+1kb. E, F and G. Histone modifications at CLU gene; ChIPs were carried out using the indicated antibodies 
and analyzed with primers encompassing the TSS region. Data from three independent ChIP assays and 
presented as % of input along with standard deviations, n=3. 
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SYNERGISTIC INHIBITION OF NB CELL GROWTH BY OF LSD1 AND N-MYC INHIBITORS  
 
The findings reported above strongly suggested that both N-Myc and LSD1 cooperatively repress 
Neuroblastoma suppressor genes such as CDKN1A(p21) and CLU. In the next set of experiments, 
it has been assessed whether pharmacological inhibition of either N-Myc or LSD1 and combination 
of both, could have functional relevance in the context of N-Myc-amplified cells. It has been 
recently reported that the small molecule 10058-F4, extensively utilized as a c-Myc inhibitor, is also 
effective on N-Myc protein and function by binding to N-Myc preventing N-Myc/MAX 
dimerization and the functional onset of N-Myc functions (184). It has been first evaluated the 
effects of these two drugs (10058-F4 and TCP) in cell cycle progression and proliferation by 
measuring respectively the level of DNA content and Ki67 protein (a marker of proliferative state) in 
Tet-21/N Neuroblastoma cell line. Flow citometry results shown in Figure 26B demonstrate that 
TCP has an earlier effect on cell cycle compared to the Myc inhibitor 10058-F4, causing a decrease 
of S phase with a G1 phase-block after 24h of treatment, while the same effect have been observed in 
10058-F4-treated cells only after 48h. In parallel, Ki67 staining reveals an earlier decrease of 
proliferative state in TCP-treated cells than in 10058-F4 -treated cells. Next, the proliferation rate of 
N-Myc amplified cell lines Tet-21/N and SKNBE was evaluated after exposing cells to TCP, 10058-
F4 alone or in combination. Both drugs affected cell proliferation (Fig26, A); however, co-treatment 
with combination of both drugs strongly inhibited the proliferation of the Neuroblastoma cells.  
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Figure 26: A) MTT assays of Tet-21/N and SK-N-BE cells treated with 1mM TCP, 75 µM 10058-F4, alone 
and in combination for 24 and 48 hours. Data from two independent experiments were used. B) Percentage 
of cell-cycle distribution of Tet-21/N and SK-N-BE (2) cells, treated with N-Myc and LSD1 inhibitors as 
indicated, was measured by Flow cytometry analysis. Cells were treated with TCP and 10058-F4 for 24 and 
48 hours and stained with Propidium Iodide for cell cycle profile; the average values from three independent 
experiments are reported in the tables; all standard deviations are <15%. C) LSD1 and N-Myc inhibitors co-
treatment increases apoptosis in NB cells. Western blotting of protein extract from Tet-21/N and SK-N-BE 
cells, treated with TCP, 10058-F4 or both for 48 hrs, using PARP (detecting both full length protein and 
cleaved fragment) CKN1A(p21) and N-Myc antibodies. Actin has been probed as loading control. 
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The strong inhibitory effect observed by drugs co-treatments result in increased apoptosis, indicated 
by the presence of a large increase of cells with fragmented sub-G1 DNA, and by reduced cell cycle 
activity, demonstrated by decreased number of cells in the S phase (Figure 6, panel B ). Western blot 
analysis was performed to determine PARP cleavage as marker of the apoptotic events correlated to 
the reduced viability observed by either TCP and 10058-F4 drugs treatment. PARP cleavage was not 
observed in TCP treated cells, and barely detectable after 10058F treatment; however, a robust 
increase of the cleaved PARP was observed in cells treated with combination of the two drugs 
(Figure 6, panel C). These findings suggest that concurrent inhibition of N-Myc and LSD1, by 
dedicated inhibitors, effectively suppress Neuroblastoma cell growth and the reduction of cell 
viability is attributable in part to increased apoptosis.  
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Discussion and final remarks 
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Neuroblastoma is one of the most common extracranial solid tumor of the childhood and is 
responsible for highest number of cancer-related deaths in infants (185). Mis-regulated expression of 
N-Myc is often found in neuroblastoma and in several other cancers, frequently of embryonic 
and/or neuroendocrine origin. So far, N-Myc amplification status remains one of the most critical 
predictor of neuroblastoma prognosis and outcome (75, 185), although other important factors have 
been identified as important for prognosis prediction.  
The current model of N-Myc functions in neuroblastoma implies both transcription activation and 
repression of selected targets involved in a wide range of biological functions through direct and 
indirect interactions with other transcription factors and histone modifiers (45).  
As extended demonstrated by a huge amount of literature data, N-Myc can regulate transcription 
events both directly bind to DNA and indirectly through other transcription factors already bound 
to regulators DNA regions. Transcriptional activation and repression events carried out by MYC 
factors is determined by recruiting of respectively co-activators and co-repressors complexes involved 
in chromatin modification and interpretation (45, 186). 
In the present work it was underlined the plastic ability of N-Myc to form two different 
transcriptional regulative complexes with two opposite members of histone methyl modifiers 
complexes: WDR5 and LSD1.  
WDR5 is an essential member of the histone H3K4 methyltransferase complex; it plays a critical 
role in transcriptional activation via binding to transcription factors and inducing histone H3K4 
trimethylation at target gene promoters (156, 180). 
In this study it has been suggested that N-Myc-WDR5 protein complex lead to a positive 
transcription regulation of MDM2 gene signature, whereas N-Myc-LSD1 determine a repression of 
CKN1A(p21) and CLU gene expression. 
MDM2 gene encodes for an E3 ubiquitin ligase involved in the physiological P53 protein 
degradation. Several cell damage signals can lead to post translational modifications of both factors 
determining an active P53 status. Then, P53 can lead to block in cell cycle progression and/or 
apoptosis events, through positive transcriptional activation of many target genes like p21 and BAX 
(187, 188). Furthermore, MDM2 can directly binds to the MYCN mRNA promoting RNA 
stabilization (189).   
In the present work, both canonical and non-canonical E-boxes were identified at the WDR5 gene 
core promoter, and confirmed that N-Myc directly binds to the WDR5 promoter and upregulates 
WDR5 mRNA and protein expression in neuroblastoma cells.  
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It has been indicated by Guccione et al. that trimethylation of H3K4 at Myc-responsive elements of 
target gene promoters is a relevant prerequisite for Myc guided transcriptional activation (70). 
However, the exact mechanism through which H3K4 is tri-methylated during Myc  transcriptional 
activation is still unknown. Genome-wide differential gene expression study with Affymetrix 
microarray shows that WDR5 siRNAs reduce the expression of several N-Myc target genes, 
including MDM2 and CCNE1, and GSEA analysis reveals that most of the genes down-regulated 
by WDR5 silencing show N-Myc/c-Myc responsive element E-box at their promoters.  
Co-Immunoprecipitation assay demonstrates that N-Myc and WDR5 form a protein complex. 
Importantly, ChIP and luciferase assays show that WDR5 and N-Myc bind to the same DNA 
region of the N-Myc target MDM2 gene promoter. Moreover, the knocking-down of WDR5 
expression reduces histone H3K4 trimethylation, reduces N-Myc protein binding to the MDM2 
gene promoter, and reduces the activity of the wild type, but not the E-box mutant, MDM2 gene 
promoter. Taken together, these data indicate that WDR5 and N-Myc form a protein complex at 
N-Myc target gene promoters, resulting in H3K4 trimethylation and transcriptional activation of N-
Myc target genes including MDM2.  
Genome-wide analyses have demonstrated that MYC factors repress at least as many targets as they 
activates. In the repression events, MYC binds to other factors and inhibits transcription of their 
downstream targets. In this way, cell cycle regulators, pro-apoptotic and cell adhesion genes can be 
repressed thus promoting rapid growth and an aggressive phenotype (190). 
LSD1/KDM1a is a lysine specific demethylase that plays an important role in stem cell biology and 
tumorigenesis, especially in the maintenance of the silencing of differentiation genes (166). 
LSD1/KDM1a is involved in maintaining the undifferentiated, malignant phenotype of 
neuroblastoma cells. Inhibition of LSD1 induces differentiation of tumor cells into post-mitotic 
neurons and blocks neuroblastoma xenograft growth (166).  
In the present study, it has been shown that LSD1 can form a tight complex with N-Myc trough 
binding to MYC box III domain. This complex determines a negative transcription regulation of 
two genes involved in neuroblastoma development and progression events, CKN1A(p21) and CLU. 
It has been shown that LSD1 and N-Myc functionally cooperates to determine transcription 
repression of CDKN1A(p21) and CLU N-Myc targets. CDKN1A(p21) is one of the major protein 
involved in negative regulation of progression through the cell cycle while CLU is a multifunctional 
protein proposed to function as a tumor suppressor in neuroblastoma (111, 191). Both N-Myc and 
LSD1 bind to chromatin promoter regions of CDKN1A(p21) and CLU, and the N-Myc binding to 
these genes is not dependent upon LSD1 recruitment. Conversely, LSD1 binding was drastically 
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reduced in cells expressing low levels of N-Myc, suggesting that LSD1 recruitment might be 
dependent upon N-Myc presence and/or abundance. Notably, LSD1 inhibition is sufficient to 
restore CDKN1A(p21) and CLU expression in presence of high levels of N-Myc. These findings 
suggest an important role of LSD1 in N-Myc mediated transcriptional repression of these gene 
targets. Collectively, these data demonstrated that N-Myc and LSD1 cooperate to repress CLU and 
CKN1A(p21) gene transcription.  
Accordingly with the cooperative effects exerted by N-Myc and LSD1 in transcriptional repression 
events, we found that combined pharmacological inhibition of N-Myc and LSD1, through the use 
of small molecule inhibitors of N-Myc and LSD1 (TCP and 10058-F4), synergistically reduces 
neuroblastoma cell viability ex-vivo through activation of the apoptotic process. This result is two-
fold important. On the one hand the combination of LSD1 and N-Myc inhibitors may have major 
therapeutic importance in the context of N-Myc-driven neuroblastoma. On the other hand it 
provides hints on the mechanism by which the N-Myc-LSD1 complex can exert its transcriptional 
effect. It may appear that N-Myc just serves as a recruiting platform of LSD1. In this case however 
the displacement of the platform by the N-Myc inhibitor would be sufficient to render LSD1 
inoperative with or without TCP. The fact that TCP sinergistically cooperates with the N-Myc 
inhibitor suggests that N-Myc and LSD1 engagement is of a particular nature; indeed, N-Myc may 
exert novel functions beyond the simple recruitment. This phenomenon may be related to the idea 
by which N-Myc and LSD1 operate in the context of different repressive complexes. It was 
previously showed the role of N-Myc in CKN1A(p21) repression through the interaction with 
positive transcription factors MIZ-1 and SP1 (86) whereas it represses CLU expression by recruiting 
the Polycomb member EZH2 (111). Furthermore, a very recent study by Laurent et al. showed that 
a specific LSD1 isoform can regulate neuronal differentiation (192).  Taken together these findings 
point to the existence of multiple and distinct N-Myc-LSD1 complexes which actuate a 
transcription repression program through definite mechanisms.  
The study carried out on N-Myc-WDR5 complex have strongly suggested the critical role of WDR5 
methyltransferase activity in facilitating N-Myc E-box occupancy at MDM2 promoter region. 
Conversely, chromatin IP experiments focused on N-Myc-LSD1 complex have revealed the clear 
involvement of N-Myc in LSD1 recruitment at CKN1A(p21) and CLU promoters. It has also been 
demonstrated the critical role of both factors in modify important histone markers like H3 
acetylation and trimethylation of lysine H3K27. Results presented in this work highlight a complex 
scenario in which the cooperation between methyl histone modifiers and N-Myc is exerted at 
different and distinct levels.  
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The possibility to specifically inhibit different N-Myc complexes function is of great importance 
since it provides the bases to the  design and development of novel therapeutic approches to treat 
MYC-induced cancers. 
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Materials and methods 
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CELL CULTURE 
 
Human neuroblastoma SK-N-BE(2)C, TET-21/N, CHP-134 and HEK 293T  cells were cultured 
in DMEM containing 10% heat-inactivated FBS and  2 mM of glutamine and antibiotics 
(penicillin, 100 U/ml; streptomycin, 100 μg/ml), in a humidified atmosphere of 5% of CO2 in air 
at 37 °C. 
When indicated, cells were treated with TCP (1mM, Enzo Life Sciences), 10058-F4 (75µM, Sigma) 
or both (1mM + 75µM) for 12, 24 or 48 hrs. Viability and apoptosis were quantified days after 
treatments by cell counting with Trypan Blue exclusion. For 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide cell proliferation assay cells were seeded at a density of 2,500 per well 
and cultured in standard medium, replaced daily. The 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay was performed according to the manufacture’s protocol 
(Roche). The Tet21/N cells were treated with tetracycline at a final concentration 
of 2 μg/ml for the indicated time 
 
FLOW CYTOMETRY ANALYSIS 
 
Cell treated as described were pelleted by centrifugation and resuspended at 1 x 10^6 cells/mL in 
Ethanol 70% in PBS at 4°C for one overnight for fixation. Then, 2 x 10^6 cells were permeabilized 
with 0,1% Triton X-100/PBS for 15’, blocked in 5% Bovine Serum Albumin/PBS and and stained 
with 2,5 µg/mL Propidium Iodide for 1hr. Cells were characterized by using a FACS Calibur (BD) 
and the data analyzed by Cell Quest Software and Cyflogic softwares.  
 
 
TOTAL RNA EXTRACTION 
 
The step by step protocol is described for cultured cells grown in two 100- mm dishes, containing 1-
1,5 x 107 cells per dish. Remove the medium and add slowly 1ml of PBS1X. Wash and remove. 
Harvest the cells using trypsin treatment and when the cells detach from the culture dish, add 1 
volume of fresh medium and transfer the suspension to a tube. Centrifuge for 5 minutes at 1000 
rpm, and then remove the supernatant. Add 1-1,5 ml of TriReagent (Sigma). Pipet gently up and 
down and incubate for 5 minutes at room temperature. Add 300 µl of chloroform and vortex for 10 
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seconds. Incubate 5- 10 minutes at room temperature. Centrifuge fo 5 minutes at 12000rpm at 4°C. 
Transfer aqueous phase in a new tube and add 750 µl of isopropyl alcohol. Mix gently and incubate 
for 5-10 minutes at room temperature. Centrifuge at 12000rpm for 10 minutes at 4°C. Remove the 
supernatant and wash the pellet with 1,5 ml EtOH 75% treated with DEPC and centrifuge at 
12000 rpm for 5 minutes at 4°C. Remove the supernatant and dry the pellet. Then, resuspend the 
pellet in 30-50 µl of DEPC-treated water and heat the sample at 55°C for 10 minutes. 
 
DNASE I TREATMENT 
 
After assessing quality of RNA purified and after quantification by spectrophotometric analysis (ratio 
260/280 > 1.8, ration 260/230 > 1.7), DNase Treatment is required to digest the contaminant 
genomic DNA. The reaction is carried out by using DNAse free-kit (Ambion) in which 5ug of RNA 
are added to DNase I Buffer and 1uL recombinant DNAse I. The reaction is performed at 37°C for 
30 minutes and recombinant DNase I is inactivated by DNasi Inactivation Reagent (0.1 volume). 
Incubate 10 min at room temperature, mixing occasionally. Centrifuge at 10000g for 2 min and 
transfer RNA to a fresh tube. 
 
REVERSE TRANSCRIPTASE REACTION 
 
The RT-PCR was designed for the sensitive and reproducible detection and analysis of RNA 
molecules in a two-step process. RT, an avian reverse transcriptase with reduced RNase H activity, 
was engineered to have higher thermal stability, produces higher yields of cDNA, and produce full-
length cDNA. cDNA synthesis was performed using total RNA (up to 1 ug) with iScript Reverse 
Transcription 5x Supermix ( RT (RNase H+), RNAse inhibitors, dNTPs, oligo (dt), random 
hexamers, buffer, MgCl2 and stabilizers) and Nuclease-free water. Prepare a master reaction mix on 
ice. Vortex this mix gently. Pipet the amount of master reaction mix into each reaction tube on ice. 
Transfer the sample to a thermal cycler preheated to the appropriate cDNA synthesis temperature 
and incubate for 5 min at 25°C (for Priming), for 30 min at 42°C (for Reverse Transcription) and 
terminate the reaction by incubating at 85°C for 5 min. Add the appropriate volume up to 100 uL 
and store at -20°C or use for qPCR immediately. Use only 2-5 ml of the cDNA synthesis reaction 
for qPCR. 
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SYBR GREEN SUPERMIX FOR REAL TIME QUANTITATIVE-PCR 
 
SsoAdvanced Universal SYBER Green Supermix (BIORAD) for ICycler CFX96 is a ready to use 
mix containing all components, except primers and template, for real time quantitative PCR 
(qPCR). It combines a chemically modified “hot-start” version of Sso7d- fusion polymerase. SYBR 
GreenER qPCR SuperMix was supplied at a 2X concentration and contains the polymerase, MgCl2, 
dNTPs SYBR Green I dye, enhancers, stabilizers and fluorescein. The protocol used for quantitative 
real time reaction is:  30 sec at 95°C (for polymerase activation and DNA denaturation, 35-40 cycles 
of:  95°C for 15 seconds and 60°C for 15-30 seconds. For multiple reactions, prepare a master mix 
of common components, add the appropriate volume to each tube or plate well, and then the 
unique reaction components (e.g. template, forward and reverse primers at 200nM final 
concentration). Cap or seal the reaction tube/PCR plate, and gently mix. Make sure that all 
components are at the bottom of the tube/plate, centrifuge briefly and place reactions in a pre-
heated real-time instrument programmed as described above. 
Melting curve analysis is a final step characterized by an increase of temperature (from 65°C to 
95°C), with an increment of 0.5°C 2-5 sec/step. 
 
STATISTICAL ANALYSIS 
 
Experiments were performed at least 3 times. Data were analyzed with Graphpad Prism 6 software 
and expressed as mean ± standard deviation (SD). Differences were analyzed for significance with 
Analysis of Variance (ANOVA) among groups or two-sided unpaired t test for two groups.  
Survival analyses and two genes correlation were performed according to the method of Kaplan and 
Meier and two-sided log-rank tests (193). Multivariable Cox regression analyses were performed. 
Probabilities of survival and hazard ratios (HRs) were provided with 95% confidence intervals (CIs). 
A probability value of 0.05 or less was considered statistically significant. All statistical tests were 
two-sided.  
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CH-IP CHROMATIN IMMUNOPRECIPITATION 
 
The step by step protocol is described for cultured cells grown in two 100- mm dishes, containing 1-
1,5 x 107 cells per dish. Two 100-mm dishes are used for each immunoprecipitation. In the specific 
case the protocol is intended for human neuroblastoma cells growing adhesively. Minor adjustments 
have to be introduced for other cell types especially for those growing in suspension. Based on our 
experience, one of the most critical steps in performing ChIP regards the conditions of chromatin 
fragmentation, which need to be empirically set up for each cell types employed. 
In each plate add 270 µl of formaldehyde from a 37% stock solution and mix immediately. Incubate 
samples on a platform shaker for 10 minutes at room temperature. In each plate add 500 ml glycine 
from a 2,5 M stock solution and mix immediately. Incubate on a platform shaker for 10 minutes at 
room temperature. Transfer the plates in ice and remove the medium. Harvest the cells with a 
scraper and then centrifuge at 1500 rpm for 4 minutes in cold centrifuge, then keep samples on ice. 
Remove the supernatant and wash pellet 3 times with 10 ml ice-cold PBS1X/ 1 mM PMSF. After 
each washing centrifuge at 1500 rpm for 5 minutes at 4°C. Remove supernatant and resuspend 
pellet in 500 µl ice-cold Cell Lysis Buffer. Pipet up and down 10- 20 times, then incubate on ice for 
10 minutes. Centrifuge at 3000 rpm for 5 minutes at 4°C. Remove supernatant and resuspend pellet 
in 600 µl ice-cold RIPA buffer. Pipet up and down 10-20 times, then incubate on ice for 10 
minutes. Sonication of crosslinked cells is performed in two distinct steps. First, cells are sonicated 
with a Branson Sonifier 2 times for 15 seconds at 40% setting. Next, cell samples are further 
sonicated with the Diogene Bioruptor for 20 minutes at high potency in a tank filled with ice/water 
in order to keep cell samples at low temperature during sonication. Centrifuge samples at 14000 
rpm for 15 minutes at 4°C. Transfer supernatant to a new tube and pre-clear lysate by incubating it 
with 50 µl of Immobilized Protein A for 15 minutes in the cold room at constant rotation. 
Centrifuge samples at 3000 rpm for 5 minutes at 4°C. Take the supernatant, after having saved 50 
µl aliquot for preparation of INPUT DNA, and add 5 µg of specific antibody. Rotate the sample 
O/N in the cold room. Add 50 µl of Immobilized Protein A and incubate by constant rotation for 
30 minutes at room temperature. Centrifuge the sample at 4000 rpm for 5 minutes at room 
temperature. Remove the supernatant and proceed to wash the beads. For each wash, incubate the 
sample by constant rotation fro 3 minutes at room temperature and the centrifuge at 4000 rpm for 2 
minutes at room temperature. Wash 4 times with 1 ml Ripa Buffer. Wash 4 times with 1 ml 
Washing Buffer. Wash 2 times with 1 ml TE buffer. Remove the supernatant and add 200 µl TE 
buffer to the beads. Add 10 µg RNAse A and incubate at 37°C for 30 minutes. Add 50 µl Proteinase 
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K Buffer 5X and 6 µl Proteinase K (19 mg/ml). Then, incubate at 65°C in a shaker at 950 rpm for 6 
hrs. Centrifuge at 14000 rpm for 10 minutes at 4°C, then transfer the supernatant (250 µl) to a new 
tube. Extract once with phenol/chlorophorm/isoamylalcohol. Recover the aqueous phase (200 µl) 
and transfer to a new tube. Add 100 µl TE buffer to the remaining phenol/chlorophorm fraction 
and re-extract DNA. Recover the aqueous phase and add it to the previous one. Extract once with 
chlorophorm/iso-amyl-alcohol. Recover the aqueous phase (200 µl) and transfer to a new tube. Add 
1 µl glycogen (Glycogen is 20 mg/ ml stock solution), 10 µg Salmon Sperm, 1/10 volumes Na-
acetate 3M pH 5.2, and 2.5 volumes of cold ethanol100% Vortex and precipitate at -80°C for 40 
minutes. Centrifuge at 14000 rpm for 30 minutes at 4°C. Remove the supernatant and wash pellet 
with 200 µl EtOH 70%. Resuspend IP-DNA and INPUT samples in 50-100 µl 10 mM TrisHCl 
pH 8. Use 2-4 µl of IP-DNA for Real Time PCR analysis. 
 
Buffers used: 
 
 
 
 
 
DUAL-STEP CHROMATIN IMMUNOPRECIPITATION 
 
The step by step protocol is described for cultured cells grown in two 100- mm dishes, containing 1-
1,5 x 107 cells per dish. Two 100-mm dishes are used for each immunoprecipitation. In the specific 
case the protocol is intended for human neuroblastoma cells growing adhesively. Minor adjustments 
have to be introduced for other cell types especially for those growing in suspension. Based on our 
experience, one of the most critical steps in performing ChIP regards the conditions of chromatin 
fragmentation, which need to be empirically set up for each cell types employed. 
Remove medium and add 2 ml PBS 1X/ 1 mM PMSF to each plate and scrape cells at room 
temperature. Pool together the cells from two plates and centrifuge at 1500 rpm for 5 minutes at 
room temperature. Wash cell pellet with 20 ml PBS1X/ 1 mM PMSF at room temperature and 
centrifuge at 1500 rpm for 5 minutes. Repeat this step 3 times. Resuspend pellet in 20 ml PBS1X/ 1 
mM PMSF. Add disuccinimidyl glutarate (DSG) to a final concentration of 2mM and mix 
immediately. DSG is prepared as a 0.5 M stock solution in DMSO. (Note1) Incubate for 45 
minutes at room temperature on a rotating wheel at medium speed (8-10 rpm). At the end of 
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fixation, centrifuge the sample at 1500 rpm for 10 minutes at room temperature. Wash cell pellet 
with 20 ml PBS1X/ 1 mM PMSF at room temperature and centrifuge at 1500 rpm for 5 minutes. 
Repeat this step 3 times. Resuspend pellet in 20 ml PBS1X/ 1 mM PMSF. Add 540 µl 
formaldehyde from a 37% stock solution and mix immediately. Incubate samples on a rotating 
wheel for 15 minutes at room temperature. Add 1 ml glycine from a 2,5 M stock solution and mix 
immediately. Incubate on a rotating wheel for 10 minutes at room temperature. Centrifuge samples 
at 1500 rpm for 4 minutes in cold centrifuge, then keep samples on ice. Remove the supernatant 
and wash pellet 3 times with 10 ml ice-cold PBS1X/ 1 mM PMSF. After each washing centrifuge at 
1500 rpm for 5 minutes at 4°C. Remove supernatant and resuspend pellet in 500 µl ice-cold Cell 
Lysis Buffer. Pipet up and down 10-20 times, then incubate on ice for 10 minutes. Centrifuge at 
3000 rpm for 5 minutes at 4°C. Remove supernatant and resuspend pellet in 600 µl ice-cold RIPA 
buffer. Pipet up and down 10-20 times, then incubate on ice for 10 minutes. Sonication of 
crosslinked cells is performed in two distinct steps. First, cells are sonicated with a Branson Sonifier 
2 times for 30 seconds at 40% setting. Next, cell samples are further sonicated with the Diogene 
Bioruptor for 20 minutes at high potency in a tank filled with ice/water in order to keep cell samples 
at low temperature during sonication. Centrifuge samples at 14000 rpm for 15 minutes at 4°C. 
Transfer supernatant to a new tube and preclear lysate by incubating it with 50 µl of Immobilized 
Protein A for 15 minutes in the cold room at constant rotation. Centrifuge samples at 3000 rpm for 
5 minutes at 4°C. Take the supernatant, after having saved 50 µl aliquot for preparation of INPUT 
DNA, and add 5 µg of specific antibody. Rotate the sample O/N in the cold room. Add 50 µl of 
Immobilized Protein A and incubate by constant rotation for 30 minutes at room temperature. 
Centrifuge the sample at 4000 rpm for 5 minutes at room temperature. Remove the supernatant and 
proceed to wash the beads. For each wash, incubate the sample by constant rotation fro 3 minutes at 
room temperature and the centrifuge at 4000 rpm for 2 minutes at room temperature. Wash 4 times 
with 1 ml Ripa Buffer. Wash 4 times with 1 ml Washing Buffer. Wash 2 times with 1 ml TE buffer. 
Remove the supernatant and add 200 µl TE buffer to the beads. Add 10 µg RNAse A and incubate 
at 37°C for 30 minutes. Add 50 µl Proteinase K Buffer 5X and 6 µl Proteinase K (19 mg/ml). Then, 
incubate at 65°C in a shaker at 950 rpm for 6 hrs. Centrifuge at 14000 rpm for 10 minutes at 4°C, 
then transfer the supernatant (250 µl) to a new tube. 
Extract once with phenol/chlorophorm/isoamylalcohol. Recover the aqueous phase (200 µl) and 
transfer to a new tube. Add 100 µl TE buffer to the remaining phenol/chlorophorm fraction and re-
extract DNA. Recover the aqueous phase and add it to the previous one. Extract once with 
chlorophorm/iso-amyl-alcohol. Recover the aqueous phase (200 µl) and transfer to a new tube. Add 
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1 µl glycogen (Glycogen is 20 mg/ ml stock solution), 10 µg Salmon Sperm, 1/10 volumes Na-
acetate 3M pH 5.2, and 2.5 volumes of cold ethanol100% Vortex and precipitate at -80°C for 40 
minutes. Centrifuge at 14000 rpm for 30 minutes at 4°C. Remove the supernatant and wash pellet 
with 200 µl EtOH 70%. Resuspend IP-DNA and INPUT samples in 50-100 µl 10 mM TrisHCl 
pH 8 Use 2-4 µl of IP-DNA for Real Time PCR analysis. 
Notes 
We have tested several crosslinking agents including DSG (disuccinimdyl glutarate), EGS [ethylene 
glycol bis(succinimidylsuccinate), DMA (dimethyl adipimidate) and DSS (disuccinidimyl suberate). 
In our conditions, DSG was the one that worked best, although we also obtained good results with 
EGS.  
Sometimes, insoluble aggregates form when DSG is added to cells resuspended in PBS 1X . 
However, this seems not to preclude the efficiency of the crosslinking reaction. 
Through this procedure we could efficiently fragment chromatin in a range between 500 and 200 
bp. As stated above, this is a critical step that must be empirically set up for each cell line tested. For 
example, HL-60 cells that grow in suspension, are sonicated with a Branson Sonifier 4 times for 30 
seconds at 40% setting and subsequently with the Biogene Bioruptor at a full power for 30 minutes. 
This procedure allows fragmentation of HL-60 chromatin to a size range of 1000-500 bp. 
 
DUAL-LUCIFERASE ASSAY 
 
The Dual-Luciferase® Reporter (DLR.) Assay System (Promega) provides an efficient means of 
performing dual-reporter assays. In the DLR. Assay, the activities of firefly (Photinus pyralis) and 
Renilla (Renilla reniformis, also known as sea pansy) luciferases are measured sequentially from a 
single sample. The firefly luciferase reporter is measured first by adding Luciferase Assay Reagent II 
(LAR II) to generate a stabilized luminescent signal. After quantifying the firefly luminescence, this 
reaction is quenched, and the Renilla luciferase reaction is simultaneously initiated by adding Stop 
& Glo® Reagent to the same tube. The Stop & Glo® Reagent also produces a stabilized signal from 
the Renilla luciferase, which decays slowly over the course of the measurement. In the DLR. Assay 
System, both reporters yield linear assays with subattomole sensitivities and no endogenous activity 
of either reporter in the experimental host cells. Furthermore, the integrated format of the DLR. 
Assay provides rapid quantitation of both reporters either in transfected cells or in cell-free 
transcription/translation reactions. The assays for firefly luciferase activity and Renilla luciferase 
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activity are performed sequentially using one reaction tube. The following protocol is designed for 
use with a manual luminometer or a luminometer fitted with one reagent injector. 
Predispense 100µl of LAR II into the appropriate number of luminometer tubes to complete the 
desired number of DLR. Assays. Program the luminometer to perform a 2-second premeasurement 
delay, followed by a 10- second measurement period for each reporter assay. Carefully transfer up to 
20µl of cell lysate into the luminometer tube containing LAR II; mix by pipetting 2 or 3 times. Do 
not vortex. Place the tube in the luminometer and initiate reading.	  	  	  
CO-IMMUNOPRECIPITATION AND GST-PULL DOWN ASSAYS 
 
The interaction between different proteins is assessed by immunoprecipitation and Western blotting. 
Cells are washed two times in PBS 1X+ PMSF (0,1%) and lysed in the following buffer for isolation 
of nuclei: Hepes 10mM, NaCl 50 mM, EDTA 1mM, DTT 1mM, NaPirophosphate 1 mM, 
NaOrtovanadate 1 mM, Nafluorophosphate 1 mM, PMSF 1 mM, protease inhibitor (Complete, 
ROCHE). Nuclei are lysed in Tris-Cl pH 7,5 50 mM, NaCl 150 Mm, EDTA 10 mM, DTT 1 
mM, protease inhibitors. Nuclear lysate (1 mg) is immunoprecipitated with specific antibody 
overnight at 4°C. The day after, specific immunoprecipitated material is incubated with 40µl of 
slurry-beads protein A, allowing the link between our specific antibody and protein A. The beads 
with immunocomplexes are washed five times with nuclear lysis buffer + NP40 0,25% and boiled in 
Laemmli sample buffer for 5 min at 100°C. Eluted proteins are separated by SDS-PAGE and 
analyzed by Western blot. 
The different N-Myc segments were cloned into the pGEX-2T plasmid, in frame with N-terminal 
GST. Recombinant proteins were expressed in E.Coli (BL21 strain), purified, and immobilized onto 
glutathione-agarose beads (Sigma-Aldrich).  
Lysis buffer: Triton 1%, lysozyme [1µg/µl], EDTA, PMSF, PBS. 
GST beads were then incubated with 40µg of HEK-293t nuclear extracts expressing LSD1_3xFlag 
protein.  
Nuclear lysis buffer: Tris-HCl pH 8 50mM, NaCl 150mM, DTT 0,5mM, sodium pyrophosphate 
1mM, sodium orthovanadate 1mM, sodium fluoride 1mM, PMSF 1mM and Complete protease 
inhibitor Roche. 
Purified complexes were separated on SDS/PAGE and analyzed by Western Blot analysis, using anti 
3xFlag monoclonal antibody (F1804 - Sigma-Aldrich) and anti GST (G7781 - Sigma-Aldrich).  	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Ripa Buffer: 
 
 Final Conc. Volume for 1 ml 
TrisHCl 1M pH 7.5 50 mM (20X) 50 ml 
NaCl 5 M 150 mM (33.3X) 30 ml 
Na Deoxycholate 5% 0.5% (10X) 100 ml 
NP40 10% 1% (10X) 100 ml 
SDS 10% 0.1% (100X) 10 ml 
PMSF 100 mM 1 mM (100X) 10 ml 
Complete Protease Inhibitors Cocktail (Roche) 50X * 1 X 20 ml 
mqH2O  680 ml 
 
Prepare a stock adding all but PMSF and Complete 50X, and store it a 4 °C. Add these 
reagents fresh to a suitable aliquot before each use. 
Dissolve 1 capsule into 1 ml mqH2O and vortex until completely dissolved. Store at -20°C. 
 
 
 
WESTERN BLOT 
 
This protocol refers typical poly-acrylamide concentrations, running and transfer times, and 
antibodies dilutions; optimize conditions for the protein you seek for. 
 
Preparation of Separating Gel: 
 
1. Assemble the BioRad casting slot. Ensure that the glasses are clean and check for 
absence of spilling from the chamber, pouring mqH2O between the glasses. Remove the 
water and dry carefully the chamber with absorbent paper. 
2. Prepare the separating gel as following (ad TEMED and APS at the end; be fast in 
casting the gel, to prevent polymerization): 
 ! 10%! 12%! 15%!40%!poly!acrylZamide! 2.5!ml! 3!ml! 3.75!ml!TrisHCl!1.5M!pH!8.8! 2.5!ml! 2.5!ml! 2.5!ml!10%!SDS! 100!µl! 100!µl! 100!µl!10%!APS! 100!µl! 100!µl! 100!µl!TEMED! 5!µl! 5!µl! 5!µl!mqH2O! To!10!ml! To!10!ml! To!10!ml!
 
 
 
3. Pour 6.5-7 ml of the solution into the chamber using a pipette. Keep the remaining to 
check for proper polymerization. Fill the chamber with isopropanol. Let it rest at least 
for 30-60’ at R.T. 
 
 
 
TOTAL PROTEIN EXCRACTS  PREPARATION AND WESTERN BLOT 
 
Check the cultured cells under an inverted microscope Detach the cells from the plate using a sterile 
scraper and pellet at 300-350 rcf for 5-10 min. at R.T. For a 6-well plate:  
• Transfer 1 ml of culture medium into a 1.5 ml-volume tube and pellet using a swing- out 
rotor.   
• Scraper the cells in the remaining volume of medium (1 ml)   
• Remove the surnatant from the tubes and add the medium where the cells were  scrapered 
in. Pellet again.   
• Meanwhile, add 1 ml of non-sterile PBS to the plate and wash the wells   
• Remove the surnatant from the tubes and add the PBS. Pellet again.   
• Remove the surnatant and wash with 1 ml PBS. Pellet.   
• Remove the PBS and resuspend the pellet in lysis buffer (20-30 µl)  For a petri dish:   
• Scraper the cells into the entire culture volume and transfer to a 15ml-volume falcon tube   
• Pellet using a swing-out rotor.   
• Meanwhile, wash the dish with 10 ml PBS   
• Remove the surnatant from the pelleted cells and add the PBS. Pellet again.   
• Remove the surnatant and wash the pellet with 5 ml PBS. Centrifuge again.   
• Remove the surnatant and resuspend the pellet into lysis buffer (approx. 100 µl). Resuspend 
the pellet into ice-cold RIPA buffer (see above for volumes) pipetting 10-15 times. Transfer 
to 1.5-volume eppendorf tubes, if necessary and incubate on ice for 10’ Sonicate for 10’ at 
max. intensity (H) using a Bioruptor immersion sonicator (fill with ice and ddH2O). 
Centrifuge for 20’ at >13000rpm at 4°C using a fixed-angle rotor. Transfer the surnatant to 
a new tube and keep it on ice for further processing ore store at -80°C.   
 
Ripa buffer: 
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Ripa Buffer: 
 
 Final Conc. Volume for 1 ml 
TrisHCl 1M pH 7.5 50 mM (20X) 50 ml 
NaCl 5 M 150 mM (33.3X) 30 ml 
Na Deoxycholate 5% 0.5% (10X) 100 ml 
NP40 10% 1% (10X) 100 ml 
SDS 10% 0.1% (100X) 10 ml 
PMSF 100 mM 1 mM (100X) 10 ml 
Complete Protease Inhibitors Cocktail (Roche) 50X * 1 X 20 ml 
mqH2O  680 ml 
 
Prepare a stock adding all but PMSF and Complete 50X, and store it a 4 °C. Add these 
reagents fresh to a suitable aliquot before each use. 
Dissolve 1 capsule into 1 ml mqH2O and vortex until completely dissolved. Store at -20°C. 
 
 
 
WESTERN BLOT 
 
This protocol refers typical poly-acrylamide concentrations, running and transfer times, and 
antibodies dilutions; optimize conditions for the protein you seek for. 
 
Preparation of Separating Gel: 
 
1. Assemble the BioRad casting slot. Ensure that the glasses are clean and check for 
absence of spilling from the chamber, pouring mqH2O between the glasses. Remove the 
water and dry carefully the chamber with absorbent paper. 
2. Prepare the separating gel as following (ad TEMED and APS at the end; be fast in 
casting the gel, to prevent polymerization): 
 ! 10%! 12%! 15%!40%!poly!acrylZamide! 2.5!ml! 3!ml! 3.75!ml!TrisHCl!1.5M!pH!8.8! 2.5!ml! 2.5!ml! 2.5!ml!10%!SDS! 100!µl! 100!µl! 100!µl!10%!APS! 100!µl! 100!µl! 100!µl!TEMED! 5!µl! 5!µl! 5!µl!mqH2O! To!10!ml! To!10!ml! To!10!ml!
 
 
 
3. Pour 6.5-7 ml of the solution into the chamber using a pipette. Keep the remaining to 
check for proper polymerization. Fill the chamber with isopropanol. Let it rest at least 
for 30-60’ at R.T. 
 
 
 
Prepare a stock adding all but PMSF and Complete 50X, and store it a 4 °C. Add these reagents 
fresh to a suitable aliquot before each use. 
Dissolve 1 capsule into 1 ml mqH2O and vortex ntil compl tely di solved. Store at -20°C. 
This protocol refers typical poly-acrylamide concentrations, running and transfer times, and 
antibodies dilutions; optimize conditions for the protein you seek for.  
 
 
 
 
 
 
 
Both total and nuclear protein extracts were loaded and separated by SDS-PAGE and Western blot 
was performed with following antibodies: N-Myc (sc-53993, Santa Cruz), LSD1 (ab17721, Abcam), 
p21 (sc-397, Santa Cruz), p53 (sc-126, Santa Cruz), Clusterin-α (sc-6420, Santa Cruz), PARP-1 (sc-
53643, Santa Cruz), Actin (sc-1616, Santa Cruz), α-actinin (sc-17829, Santa Cruz), WDR5(abcam-
56919), MDM2(Abcam-3110) And CCNE1(Abcam-5979). 	  
SIRNA TREATMENTS SH-RNA PRODUCTION AND SILENCING ASSAYS.  	  
20 or 100nM siRNA targeting LSD1 (GE Dharmacon), N-MYC (Qiagen), WDR5(Qiagen) or 
scramble were transfected in SHEP Tet-21/N and SK-N-BE (2)-C cells using Lipofectamine 2000 
(Invitrogen), in according to the protocol described in manufacturer. In Tet-21/N cells N-Myc was 
turned off by the addiction of tetracycline 1µg/ml for one week before treatment. In ChIP analysis 
sh-RNA silencing was performed as described  in the next paragraph. Briefly, virus production was 
carried out on HEK 293T cells transfected (Effectene QIAGEN) with packaging vectors, pMD2.G 
(#12259 - Addgene) and psPAX2 (#12260 - Addgene), and pLKO.1 TRC ShRNA backbone 
plasmids. pLKO.1 TRC Lentiviral Non-targeting ShRNA control (#RHS6848) and pLKO.1 TRC 
Lentiviral ShRNA LSD1 (Clone ID-TRCN0000046068) were purchased at Open Biosystems-GE 
Dharmacon. Optimization experiment (1–100 multiplicity of infection, MOI) was carried out on 
Tet-21/N cells using puromycin kill curve (1 µg/ml) and set at MOI 10. For shRNA Chip 
experiments Tet-21/N cells were transduced for 6 hours with MOI 10 and polybrene concentration 
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set at 10µg/ml, selected with puromycin for 24 hours and then incubated for 24 hours with 
complete media without puromycin selection.  
 
PRODUCTION OF TRC VIRAL SUPERNATANT 
 
We routinely use QIAGEN Effectene Transfection Reagent, which works very well for us. Detailed 
protocols are provided with the kit. The protocol below has been slightly modified from the 
QIAGEN kit protocol, in that it uses slightly more DNA. 
 
Reagents: 
• 293T cells (ATCC) 
• 293T is a highly transfectable derivative of the 293 cell line into which the 
• temperature sensitive gene for SV40 T-antigen was inserted. 
• Cell culture medium 
• Effectene reagent (Qiagen) 
• EC buffer (comes with the QIAGEN Effectene kit) 
• Enhancer (comes with the QIAGEN Effectene kit) 
• TRC plasmid DNA (purchased from the RNAi Core Facility) 
• psPAX2 (Addgene) _This is the packaging vector 
• pMD2.G (Addgene) _This is the envelope vector 
• 0.45 µm filter (Millipore) 
 
 
Method: 
 
Day 1: Plate 1.0x106 to 1.2x106 293T cells in a 6-well plate. 
Day 2: a. In a sterile microfuge tube, combine 1 µg of TRC or pGIPZ plasmid 
DNA with 1 µg psPAX2 and 0.5 µg pMD2.G (2:2:1 ratio) in 100 µl EC buffer. Add 3.2 µl 
Enhancer. Mixed by brief vortexing and then spin down to collect the contents of the tube. Incubate 
at room temperature for 5 minutes. Add 10µl Effectene reagent, mix by brief vortexing and incubate 
for another 20-30 minutes at room temperature. 
b. During the incubation, re-feed the 293T cells (that have been plated out the day before) with 1.6 
ml of fresh medium 293T cells peel off easily, use extreme care to re-feed the cells. 
	   81	  
c. After the 20-30 minute incubation, add 0.6 ml medium to the DNA-Effectene mixture. Mix well 
and drop carefully onto the cells. 
Day 3: Re-feed the transfected cells with 2.5 ml fresh medium. 293T cells peel off easily, use extreme 
care to re-feed the cells. 
Day 4: 48 hours after infection, filter the supernatant through a 0.45 µ filter, aliquot and store at -
80°C until ready for use. 
 
INFECTION USING TRC VIRAL SUPERNATANT 
 
The following protocol works well with most commonly used cancer cell lines. However, be aware 
that some cells, particularly primary cells, are extremely sensitive to Polybrene. It is therefore a good 
idea to pre-determine the most suitable concentration of Polybrene to be used in the infection. 
 
Reagents: 
 
Cells of interest to be infected (in this work: TET-21/N)  
Cell culture medium, DMEM + 10% FBS 
Viral supernatant (sh-RNA LSD1 or sh-RNA non-silencing)  
Polybrene, 1 µg/µl (Sigma) 
Puromycin (various sources such as Sigma and Clonetech)  
 
The ideal concentration of puromycin should be pre-determined based on the cell line. 
 
Method: 
Day 1: Plate 1x105 to 1.25x105 cells per well in a 6-well plate. 
Day 2: Aspirate the medium and infect cells with 250 to 500 µl viral supernatant. Add fresh 
medium to a final volume of 1 ml. Add 10 µl (or predetermined optimized amount) of 1 µg/µl 
Polybrene. 
Day 3: Re-feed the cells with fresh medium. 
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PLASMID CONSTRUCTION 
 
To generate the pGL3-basic MDM2 WT reporter vector, the MDM2 human promoter region 
containing the putative N-Myc binding site (E-box) was first amplified by PCR from genomic DNA 
(the primers used were reported on Primers table). The MDM2 promoter segment was cut with 
KpnI and XhoI and subcloned into the luciferase pGL3-basic promoter vector (Promega 
Biosciences, Promega Corp., San Luis Oispo, CA). The pGL3-basic MDM2 MUT reporter vector 
was obtained by mutation of the E-box sequence located at 444 bp from the transcription start site 
by whole around PCR mutagenesis. The LSD1 expression vector was obtained by amplifying LSD1 
coding sequence (NM_015013.3) by PCR and then cloned into pCMV14-3Xflag using primers 
reported into Table of Primers. All the PCR products was ligated by using T4 DNA ligase (NEB) 
and verified by sanger sequencing. The pGL3 MDM2 WT or the pGL3 MDM2 MUT reporter 
vectors were transiently transfected using Lipofectamine LTX reagent (Invitrogen). Luciferase assays 
were valueted 48h post transfections. pCMV14-LSD1-3Xflag were were transiently transfected using 
Lipofectamine LTX reagent (Invitrogen). 
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TABLE OF PRIMERS USED FOR QRT-PCR, CH-IP AND CLONING 
 
Name                                  Sequence FW                                            Sequence RV 
 
N-Myc_qRT-PCR CACAAGGCCCTCAGTACCT TGACCACGTCGATTTCTTCCT 
WDR5_qRT-PCR CACGCTGGACAACACTCTGA GTGGCCAGTGTACGTCTTCA 
GUSB_qRT-PCR GTGGGCATTGTGCTACCTC ATTTTTGTCCCGGCGAAC 
B2M_qRT-PCR GTATGCCTGCCGTGTGAACC GCGGCATCTTCAAACCTCCA 
MDM2_qRT-PCR AGGAGATTTGTTTGGCGTGC TGAGTCCGATGATTCCTGCTG 
CCNE1_qRT-PCR CAGGGAGCGGGATGCG GGTCACGTTTGCCTTCCTCT 
CKN1A(p21) _qRT-PCR TCACTGTCTTGTACCCTTGTGC GGCGTTTGGAGTGGTAGAAA 
LSD1_qRT-PCR TGGCTGTGGTCAGCAAACAA TTTCTCTTTAGGAACCTTGACAGTG 
CLU_qRT-PCR GAGCAGAGCGCTATAAATACGG CCAATTCTGGAGTCTTTGCAC 
WDR5 Amplicon A ChIP CTAAAACAGGCTGGTGTTCTGC CTAAAACAGGCTGGTGTTCTGC 
WDR5 Amplicon B ChIP TAGGAAGTGCATTAGAAGGGCC CAACGCTTTAAAGGGACAGCAC 
WDR5 Amplicon C ChIP CAGAAGCTTCCAAACCGCAC GGACCGGGTGGAGGGAACTG 
MDM2 Amplicon A ChIP GGCGAAACCCCATCTCTAGTAA TCTGCCTTAGCCTCCTGAGTAT 
MDM2 Amplicon B ChIP TTCCCAGCCTCTGCCCGTTC TCCGAAATCCCGCCCTCCTC 
Cdkn1A(p21)-3,3kb Ch-IP CCAGCTGGCTGATGTTAACAAC TGGTCA TCACACCTGCT A TGTC 
Cdkn1A(p21) TSS Ch-IP TGGCAGA TCACA T ACCCTGTTC CTCTCTCACCTCCTCTGAGTGCC 
Cdkn1A(p21)-2,2kb Ch-IP GCTGGTGGCTA TTTTGTCCTTG TGGCAGA TCACA T ACCCTGTTC 
CLU -1,0kb Ch-IP TCCATAGTCCTGATCCTGAACTG TTTGGAGCCAGGGATGTTTAAG 
CLU TSS Ch-IP TTGAGCAGAGCCACACCAGGAC TGCGAGCTGTGTCA TCCCTCTC 
CLU +1kb Ch-IP GTGGAGCATTGGGCACAACTG CCAGAGGCAAAGGTTAGCACTG 
LSD1-3xFlag cloning AAGGTACCATGTTATCTGGGAAGAAGGC AATCTAGACATGCTTGGGGACTG 
pGL3-MDM2 promoter 
cloning 
AAGGTACCTGGGAAAGTAGGTGAGT- 
-CAGAATG 
AACTCGAGGACATGTTGGTATTGCACAT- 
-TTGCCTAC 
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